Trading resumed

Halted???

Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refr...
Print
Alert
Cell Therapeutics, Inc. (MM) (NASDAQ:CTIC)
Intraday Stock Chart
Today : Thursday 10 May 2012


Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization from the European Commission ("EC") for Pixuvri® (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas ("NHL"). Pixuvri is the first approved treatment in the European Union ("EU") in this patient setting.

(Photo: http://photos.prnewswire.com/prnh/20120510/SF05192)

The decision allows CTI to market Pixuvri in the 27 Member States of the EU as well as in Iceland, Liechtenstein and Norway. CTI expects to make Pixuvri immediately available in the EU, initially through a named patient program. CTI plans to market and commercialize Pixuvri with its own sales force in the EU starting in the 2nd half of 2012.

"Pixuvri is a welcome addition in our efforts to control disease progression in these late-stage aggressive NHL patients as it has demonstrated a significant benefit compared to standard treatments used at this stage of disease. By addressing this unmet need, Pixuvri adds an important treatment option for patients," said Norbert Schmitz, M.D., Ph.D., Head of the Department of Hematology, Askelepios Klinik St. Georg in Hamburg, Germany.

"The EC's decision for Pixuvri is an important milestone for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas who currently have no approved option to treat their disease, and we are moving rapidly to make this product available for patients in the EU," said James A. Bianco, M.D., CEO of CTI.

The PIX 301 phase 3 clinical trial, which formed the basis for the marketing authorization application, demonstrated that a greater proportion of patients achieved a complete response or unconfirmed complete response to Pixuvri than a comparator chemotherapy medicine, (20% versus 6%) and patients receiving Pixuvri survived for longer without their disease progressing (an average of 10.2 months versus 7.6 months). The most frequent side effect seen in the clinical studies was suppression of the patient's bone marrow, resulting in low levels of white blood cells, platelets and red blood cells. Infections were common, but were only serious in a few patients. The Summary of Product Characteristics ("SmPC") will include the full prescribing information, including the safety and efficacy profile of Pixuvri in the approved indication. The Summary of Product Characteristics, which will be published in the European Public Assessment Report is expected to be posted to the European Medicines Agency's (the "EMA") website (http://www.ema.europa.eu) in the next few weeks.

Indication and Dosing

Pixuvri will be marketed in the EU as Pixuvri 29 mg powder for concentrate for solution for infusion; and is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of Pixuvri treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.

One vial of Pixuvri contains 29 mg pixantrone (as dimaleate), and must be reconstituted and diluted before use. The recommended dose is 50 mg/m2 of Pixuvri base on days one, eight, and 15 of each 28-day cycle for up to six cycles. However, the dose has to be adjusted before the start of each cycle based on nadir hematologic counts or maximum toxicity from the preceding cycle of therapy. The amount of Pixuvri in milligrams that is to be administered to a patient should be determined on the basis of the patient's body surface area ("BSA").

About Conditional Marketing Authorization

Similar to accelerated approval regulations in the United States, conditional marketing authorizations are granted in the EU to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit. A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorization for Pixuvri, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.

The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after 1 to 3 prior regimens for aggressive B-cell NHL and who are not eligible for autologous stem cell transplant ("ASCT") . As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.

About Non-Hodgkin Lymphoma

NHL is caused by the abnormal proliferation of lymphocytes, cells key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms—aggressive and indolent NHL. Aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly. The World Health Organization's International Agency for Research on Cancer's 2008 GLOBOCAN database most recent estimates state that in EU approximately 74,162 people will be diagnosed with NHL and 31,371 are estimated to die from NHL every year.

There are many subtypes of NHL, but aggressive B cell NHL is the most common and accounts for about 60% of cases. Initial therapy for aggressive NHL with anthracycline-based combination therapy cures up to 60% of patients. Of the remaining patients, approximately half will respond to intensive second-line treatment and some are cured by stem cell transplantation. Of those not eligible for intensive second line therapy and those patients who fail to respond or relapse, until the approval of Pixuvri, no therapeutic has received regulatory approval for this patient group.

About Pixuvri (pixantrone)

Pixantrone is a novel aza-anthracenedione with unique structural and physio-chemical properties. Unlike related compounds, pixantrone forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related antineoplastic compounds. Pixantrone was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity. These novel pharmacologic properties allow pixantrone to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity, and because pixantrone is not a vesicant, allow it to be safely delivered via a peripheral intravenous catheter. At the time of grant of marketing authorization by the European Commission, Pixuvri is not yet approved in the United States.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our website, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of Pixuvri include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Pixuvri in particular, including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the U.S. Food and Drug Administration, that Pixuvri may not be immediately available to patients in the EU, that CTI may not market and commercialize Pixuvri with its own sales force in EU starting in the second half of 2012, that patients may experience side effects from Pixuvri other than suppression of bone marrow, that CTI may not be able to complete the PIX306 clinical trial of Pixuvri-rituximab compared to gemcitabine-rituximab in patients who have relapsed after 1 to 3 prior regimens for aggressive B-cell NHL and who are not eligible for autologous stem cell transplant ("ASCT") by June 2015 or at all as required by the EMA or have the results of such trial available by June 2015 or at all, that CTI may not be able complete a post-marketing study aimed at confirming the clinical benefit observed in the PIX 301 trial, that the conditional marketing authorization for Pixuvri may not be renewed, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling Pixuvri, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

European Information:

Elena BellaciccaT: +39 02 89659700 E: EBellacicca@cti-lifesciences.com

U.S.

Media Contact:

Dan EramianT: 206.272.4343C: 206.854.1200E: media@ctiseattle.com www.CellTherapeutics.com/press_room

Investors Contact:

Ed BellT: 206.272.4345

Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: invest@ctiseattle.comwww.CellTherapeutics.com/investors

SOURCE Cell Therapeutics, Inc.

PSGY.. opps forget it..old news from 2011

CAVU Resources, Inc. Acquires 40% Of CAVU Global Energy, LLC With Over
$200 Million In Contributed Assets


TULSA, Okla., May 10, 2012 /PRNewswire via COMTEX/ -- CAVU Resources, Inc.
("CAVU"), which trades as OTC:CAVR.PK, announced today that it has closed on a
joint venture agreement and has acquired 40% of the newly formed company called
CAVU Global Energy, LLC, ("CAVU Global"). Investors have contributed a new
mobile oil refinery technology and oil and gas leases in three states with
reserve and technology values in excess of $200 million dollars. CAVU Global
brings funding commitments and in addition also has ongoing negotiations for up
to $25 million to fund the company's initial projects.

The new partnership has targeted specific opportunities in the oil and gas
business focusing primarily on the development of properties in Oklahoma, Texas
and Louisiana. CAVU Global also will begin the immediate placement of its
revolutionary technology that allows mobile mini refineries to be moved directly
on to production sites with as small as 100 barrels a day of production.

A pilot plant has already been built proving out the technology in Nevada. The
initial mobile refinery plant has been successful in both tar sand oil and
conventional oil conversions allowing fuel production in remote areas, opening
both civilian and government opportunities for the company. This will allow for
a lower cost fuel direct to the consumer for gas and diesel. By eliminating
transportation and marketing costs, this allows for high grade fuel to possibly
be sold at costs 20 to 30% lower than current retail gas stations.

CAVU Energy Systems, Inc. will continue as the Bonded operating company and run
all the oil and gas operations for the proposed multi state operations. CAVU
Energy will also handle the installation of the Mobile refineries on a worldwide
basis.

"We are extremely impressed with the capability of CAVU Resources, Inc. After 9
months of discussions, we feel CAVU is the right fit helping us to develop our
oil and gas leases in an expedited fashion," stated Chris Wilks, managing member
of CAVU Global Energy, LLC.

"We have closed this agreement and there is no dilution or further equity
issuance related to this Joint Venture. CAVU's 40% ownership now brings in
excess of a $200 million asset base to accelerate its growth, and also secures
the spinout and planned public offering of CAVU Energy Systems, Inc. The
reserves and projected income from the current projects inside CAVU Global
should allow CAVU to exceed all previous earnings projections, and future
earnings per share could easily be 2 to 3 times the current stock price. The
last year has been focused on eliminating debt, and creating opportunities for
the company with the final goal to have cash flow and earnings. The
infrastructure is now fully in place and we are finally there, after having
worked on closing this deal for the last 9 months, the projected cash flow from
this acquisition should eliminate the need to sell equity in the future to fund
operations, debt retirement and growth. The combined team of CAVU and CAVU
Global creates a financial and asset based relationship that should provide
multiple future benefits to our shareholders and to meet all these goals,"
stated William Robinson, CEO and President of CAVU Resources, Inc.

About CAVU Global Energy, LLC CAVU Global Energy was formed with the goal of
becoming a nationally known oil and gas company dedicated towards the
communities in which it operates by focusing on price competitive markets. This
family run company features a fully qualified membership which includes
entrepreneurs, former VP of a Global Government Retailer (AAFES), and a retired
chief engineer for ATK, a major NASA contractor. With a combined experience of
over 60 years, CAVU Global Energy is leading the way towards achieving its goals
in the oil and gas business. CAVU Global Energy has secured contracts for both
drilling and sales of output production. CAVU Global Energy in addition,
qualifies as a Minority owned company.

About CAVU Resources, Inc. During World War II, Navy fighter pilots would look
up at the sky and if it was a "CAVU" day then it meant ceiling and visibility
unlimited. The pilots believed they would have unobstructed flying allowing them
to see their targets quicker, identify the obstacles they needed to overcome,
giving them a greater chance of success. The founders of CAVU Resources, Inc.
chose the name CAVU because they believe that the company will be the embodiment
of its name.

CAVU was formed with the goal of becoming a recognized regional player in the
independent oil and natural gas industry by growing the company's oil and
natural gas reserves. CAVU is a natural resource company engaged in the
acquisition, exploration and development of oil and natural gas properties. The
Company operates in the upstream segment of the oil and gas industry with
planned activities including the drilling, completion and operation of oil and
gas wells in Oklahoma, Kansas, Colorado, Montana and Texas. The Company has
acquired leases and is currently exploring additional opportunities in oil and
gas leases.

CAVU's has a minority subsidiary interest in CAVU Energy Services, Inc., a
bonded Oil and Gas Operating Company manages the company's properties in
Oklahoma and plans to operate targeted leases in Kansas, Colorado, Montana and
Texas. CAVU plans to utilize its own operating equipment and with strategic
partners provide contract drilling, fracture stimulation and directional
drilling services to oil, natural gas exploration and production companies. CAVU
plans to expand operations not only in the traditional Oil and Gas business, but
also to invest in technology, waste disposal, and water reclamation, taking
advantage of the changing environment and in the world's need for new, green and
innovative resources. More information is available at the company's website at
http://www.cavu-resources.com.

Cautionary note: This report contains forward-looking statements, particularly
those regarding cash flow, capital expenditures and investment plans. Resource
estimates, unless specifically noted, are considered speculative. By their
nature, forward-looking statements involve risk and uncertainties because they
relate to events and depend on factors that will or may occur in the future.
Actual results may vary depending upon exploration activities, industry
production, commodity demand and pricing, currency exchange rates, and, but not
limited to, general economic factors. Cautionary Note to U.S. investors: The
U.S. Securities and Exchange Commission specifically prohibits the use of
certain terms, such as "reserves" unless such figures are based upon actual
production or formation tests and can be shown to be economically and legally
producible under existing economic and operating conditions.

Contacts: Specialty Situations Investor Relations Tel: 973-507-6199



CAVR.PK

CAVU Resources, Inc. CAVU Global Energy, LLC

5147 South Harvard Ave, STE 138 Chris Wilks, Managing Partner

Tulsa, OK 74135 Edward Wilks- Managing Partner

Desai V. Robinson, Director of Public Relations Rodney Wilks- Lead Engineer

Email: info@cavu-resources.com Email: cwilks@cavuglobalenergy.com

Website: www.cavu-resources.com ekwilks@sbcglobal.net

Tel: 504-722-7402 Tel: 214-289-3195

WORCESTER, Mass. and TORONTO, May 9, 2012 /PRNewswire via COMTEX/ -- Generex
Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a Scientific
Advisory Board (SAB) has been established for its wholly-owned oncology
immuno-therapeutics subsidiary, Antigen Express, Inc.

The function of the SAB is to provide advice and assistance to Antigen Express
in respect of the clinical and regulatory programs for the Company's
immuno-therapeutic cancer vaccines. The initial focus of the SAB will be to
review the Phase II clinical trial of the Antigen Express AE37 breast cancer
vaccine and facilitate the transition into a Phase III clinical trial.

The inaugural meeting of the SAB will take place in Dallas, TX May 18 & 19,
2012.

Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P.

Generex is pleased to announce that Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P.
has agreed to join the SAB.

Dr. Hortobagyi chairs the department of Breast Medical Oncology and directs the
Breast Cancer Research Program at the University of Texas MD Anderson Cancer
Center, where he also serves as Professor of Medicine and holds the Nellie B.
Connally Chair in Breast Cancer.

Dr. Hortobagyi's research includes combination chemotherapy regimens,
pre-surgical chemotherapy, and targeted therapies for all stages of breast
cancer. He has contributed more than 900 articles to scientific journals,
authored and co-authored 13 books, and contributed over 140 chapters to
textbooks.

For his efforts in breast cancer research, Dr. Hortobagyi has received worldwide
honors. In 2001, President Jacques Chirac named him Chevalier of the Order of la
Legion d'Honneur de France. In 2003, Dr. Hortobagyi received the Glen Robbins
Award in Breast Cancer Research from the New York Cancer Society and the
Metropolitan Breast Cancer Group, and the Bristol-Myers Squibb 2003 Horizon
Scientific Award. The Mexican Society of Oncology named him the 2005 World
Leader in Oncology.

Dr. Hortobagyi was elected President of the American Society of Clinical
Oncology (ASCO) for the 2006-2007 term; he serves on the Board of Directors of
the Conquer Cancer Foundation. He served as President of the International
Society of Senology and as a member of the Board of Governors of The
International Association for Breast Cancer Research. He chairs the Breast
Committee of the Southwest Oncology Group and for 20 years he chaired the Data
and Safety Monitoring Committee of the National Surgical Adjuvant Breast and
Bowel Project.

"Our goal here is to create a world-class collective of thought and opinion
leaders in the breast cancer field," commented Mark A. Fletcher, Generex
President & Chief Executive Officer. "Dr. Hortobagyi will proffer his vast
experience and expertise to Antigen Express as we transition into a Phase III
clinical trial of the AE37 breast cancer vaccine."

About AE37 and Ii-Key Hybrid Platform TechnologyAntigen Express is a platform
technology and product-based company developing proprietary vaccine formulations
for large, unmet medical needs. The Company's Ii-Key Hybrid technology platform
entails the modification of fragments of antigens to increase their potency in
stimulating critical members of the immune response, known as CD4+ T helper
cells. Incorporating the Ii-Key modification along with tumor-associated
antigens can greatly enhance the immune system's ability to recognize and
destroy cancer cells bearing any of the targeted antigens as well as increasing
immunological memory.

The first product candidate utilizing the Company's novel Ii-Key Hybrid
technology platform is a HER-2/neu Peptide Vaccine (AE37). This "off-the-shelf"
cancer immunotherapy product candidate is easier and less costly to produce than
comparable cell-based approaches. AE37 is derived from a peptide fragment of the
human epidermal growth factor receptor 2 (HER2) oncoprotein, which is expressed
in a variety of tumors including 75-80% of breast cancers as well as a high
percentage of prostate, ovarian and other cancers. AE37 represents the only
HER2-based peptide vaccine currently being studied in a randomized trial and its
use is not restricted to patients with a particular type of human leukocyte
antigen (HLA) peptide.

About Breast Cancer

According to the American Cancer Society, more than 232,000 women will be
diagnosed with breast cancer, and nearly 40,000 will die from the disease, in
2012. For women whose cancer tests positive for increased quantities of the
HER2, approved targeted therapies include trastuzumab (Herceptin®;
Roche-Genentech). However, only 25% of breast cancer patients have HER2 levels
high enough to be eligible for Herceptin. AE37 is positioned initially as an
adjuvant therapy for at least 50% of breast cancer patients; i.e., those with
low-to-intermediate levels of HER2 expression.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist(TM)
device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core
platform technologies of Antigen Express comprise immunotherapeutic vaccines for
the treatment of malignant, infectious, allergic, and autoimmune diseases.
Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in
immunotherapy. One of its platform technologies relies on inhibition of
expression of the Ii protein. Antigen Express scientists, and others, have shown
clearly that suppression of expression of the Ii protein in cancer cells allows
for potent stimulation of T-helper cells and prevents the further growth of
cancer cells. For more information, visit the Generex website at www.generex.com
or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plan," "believes," "will," "achieve,"
"anticipate," "would," "should," "subject to" or words of similar meaning, and
by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and uncertainties,
some of which are known and others of which are not. Known risks and
uncertainties include those identified from time to time in the reports filed by
Generex with the Securities and Exchange Commission, which should be considered
together with any forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by
regulatory agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements regarding the
expected timing of clinical trials or ultimate regulatory approval cannot be
regarded as actual predictions of when Generex will obtain regulatory approval
for any "phase" of clinical trials or when it will obtain ultimate regulatory
approval by a particular regulatory agency. Generex claims the protection of the
safe harbor for forward-looking statements that is contained in the Private
Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation



www.prnewswire.com


Copyright (C) 2012 PR Newswire. All rights reserved

-0-




KEYWORD: Massachusetts

Canada

INDUSTRY KEYWORD: HEA

MTC

SUBJECT CODE: PER

CXP

Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a completely revised new website at www.vitrobiopharma.com. Vitro Biopharma is focused on providing unique tools for stem cell research and clinical development based on adult stem cells known as Mesenchymal Stem Cells or MSCs. These adult stem cells represent the fastest growing segment of the stem cell industry largely because of the availability of these cells from several tissue sources and the ever-increasing evidence for clinical effectiveness in the treatment of a variety of diseases, injuries and regenerative medicine applications. Vitro Biopharma is pleased to announce the launch of a completely revised and newly formatted website featuring E-commerce capabilities, a considerably expanded product offering, enhanced and readily accessible information for investors together with improved navigation, communication with the Company and ease of use.
Dr. Jim Musick, Vitro Biopharma's President and CEO, said, "We are very pleased to announce the launch of our new robust website featuring online ordering from an expanded product menu & a fully integrated investor relations platform. We believe that E-commerce capabilities will expand our abilities to reach new customers, especially those customers located in other time zones. We are offering free shipping for all domestic orders. We are targeting key stem cell researchers and enhancing our abilities to deliver our products to them. The integration of our fully dynamic shopping cart allows Vitro to be competitive internationally. The investor relations platform will allow us to better communicate with our shareholders.

We have expanded our products that now include about 60 products by addition of new cell culture media formulations and additional stem cell products derived from differentiated stem cells including native and fluorescent-labeled cells for advanced studies of stem cell therapies. We also plan additional new product introductions in the near future to further expand our offerings to the markets we serve. We are continuously fostering collaborative relationships with our colleagues and customers to rapidly develop the potential of stem cell therapy into new treatment options for those patients who could benefit the most from these developments."

To receive timely information on Vitro Biopharma, when it hits the newswire, sign up for Vitro Biopharma email news alert system today at: http://vitrobiopharma.com/ir_platform/email-alerts/

About Vitro Biopharma, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG) (http://www.vitrobiopharma.com), owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, MSC-Gro™ optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro has established a strategic alliance with HemoGenix®, Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute LUMENESC™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents. During 2011, the Company out-licensed its patents and related intellectual property for FSH generation and production to Dr. James Posillico, Ph.D., a global leader in women's healthcare. FSH is a widely used hormone to treat infertility that continues to be a global health issue. The Company is actively assisting Dr. Posillico to develop distribution channels for therapeutic FSH into international markets.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

This information was brought to you by Cision http://www.cisionwire.com

http://www.cisionwire.com/vitro-biopharma--inc/r/vitro-biopharma-launches-new-website,c9257449

The following pictures are available for download:

[Image] VODG Logo
CONTACT: Dr. Jim Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: Jim@vitrobiopharma.com
Connect with Jim on Linkedin

Riverdale Oil and Gas Corporation (RVDO.PK) Announces the Lampley #1R
Well Completion


AUSTIN, TX, May 09, 2012 (MARKETWIRE via COMTEX) -- Riverdale Oil and Gas
Corporation (PINKSHEETS: RVDO) continues to increase its assets with small
percentages of ownership, acquired at low costs, and minimal risk exposure.
Riverdale's growing asset base will provide it with a continual funding source
on which to build.

Riverdale has announced a significant discovery in the Lampley #1R well located
in Lavaca Co., Texas. The well recently tested a half a million cubic feet (510
MCF) gas per day on a very small 7/64" diameter choke, flowing at 1960# of
pressure, from perforations at 5384'-5388'. The tests ranged up to a million
cubic feet of gas per day (1000 MCF). The well test revealed condensate, which
is estimated to be in the range of 25 to 30 barrels per day per 1000 MCF of gas.
Riverdale owns a 1.667% carried working interest in this well. The Lampley #1R
is one of the first wells to be readied for production that is owned by
Riverdale. Plus, two other wells in the completion phase are described in the
following paragraphs.

The Blue Wing Lee #1 well in Victoria Co., Texas, a recent Riverdale
acquisition, is waiting on field equipment and its pipeline connection to begin
selling approximately 300 MCF gas per day. The well tested around 600 MCF per
day on a small choke and has 740# shut-in pressure. The equipment installation &
pipeline hookup are expected to be finished by the end of this month. Riverdale
owns a 1% carried working interest in this well.

BRIDGEWATER, N.J., May 9, 2012 /PRNewswire via COMTEX/ -- Energy Edge
Technologies Corporation (OTCBB: EEDG) has entered into a Strategic Alliance as
a Business Partner with 5LINX, one of the fastest growing privately held
companies in America as recognized by Inc. 500 Magazine. The agreement gives
Energy Edge the opportunity to provide residential consumers with savings on
their electric and gas bills in all deregulated states, as well as adding a
significant new cost savings component to EEDG's commercial and government
energy projects.

5LINX achieved revenues of $50 Million in 2010, over $100 Million in 2011, and
is projecting sales to more than double again in 2012. The company currently has
260 corporate employees and over 75,000 independent marketing representatives
worldwide. 5LINX was recently named the 76th largest direct sales company in the
world by Direct Selling News, placing them on an exclusive list with the likes
of Avon, Tupperware, and Mary Kay.

www.5LINX.com/products/5linx-energy-program/

"Adding the ability to help residential consumers switch to more competitive
rates for electricity and gas through 5LINX is a natural extension of our
success in the commercial, industrial and government sectors," stated Robert
Holdsworth, President of EEDG. "The 5LINX program represents an enormous
opportunity for EEDG to add immediate revenues and income for our shareholders
as well as the perfect vehicle for us to deliver on our ongoing commitment to
build a national sales force of highly skilled Military Veterans."

Energy deregulation represents a $500 Billion market of which approximately 90%
of consumers have not yet switched to a lower cost energy supplier. 5LINX is
successfully competing with traditional utilities by buying energy in the
wholesale market and delivering it to consumers at a lower cost, using that same
utility's own infrastructure. With deregulation scheduled to take effect in all
50 states by 2015, 5LINX is positioned to provide customers and business
partners across America with outstanding value and revenue potential.

"Warren Buffet stated in Forbes Magazine that the deregulation of energy will
create The Largest Transfer of Wealth in History, and 5LINX has been moving very
aggressively to take full advantage of this unique opportunity," said Terrence
Porter, Senior Vice President of 5LINX. "We are in the business of building
lucrative long-term residual income streams for our business partners and
independent representatives and believe that Energy Edge could be one of the
most successful and gratifying alliances we have formed. 5LINX has long been
committed to supporting our nation's Military heroes and by partnering with
Energy Edge and VetPower.org, the 'Investing in Veterans' charity that EEDG has
so generously funded from the start, we will now be able to positively impact
the lives of literally thousands of Veterans and their families," concluded
Porter.

Energy Edge (EEDG.OB) provides comprehensive "whole facility" energy efficiency
projects to reduce operating costs and CO2 emissions for new and existing
buildings. www.energyet.com

Contact:Jerry JenningsEmerson Gerard Associates
561-881-7318jerry@emersongerard.com

SOURCE Energy Edge Technologies Corporation



www.prnewswire.com


Copyright (C) 2012 PR Newswire. All rights reserved

-0-




KEYWORD: New Jersey

INDUSTRY KEYWORD: OIL

UTI

EUT

GAS

SUBJECT CODE: JVN

CXP

Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer


May 8, 2012 (GlobeNewswire via COMTEX) -- -- TESEGAST Trial Opens in U.S., EU,
and Asia

-- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2nd-Line Treatment

BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- announced today that the
first patient has been accrued to a new randomized clinical trial of its lead
compound, tesetaxel, in patients with advanced gastric cancer. The trial, known
as TESEGAST, is a randomized, double-blind, placebo-controlled study that is
expected to accrue approximately 260 patients. The trial will be conducted at
approximately 40 sites worldwide, including the U.S., Western Europe, and Asia.
Accrual is projected to take approximately 12-15 months, with approximately 9
months of followup after the last patient is randomized.

The trial will enroll patients with advanced gastric cancer who have measurable
disease that has progressed after initial chemotherapy. Prior treatment must
have included a platinum-containing drug and a fluoropyrimidine. Testing for
HER2 expression is required; HER2+ patients must have received and progressed on
trastuzumab (Herceptin(R); Hoffmann La Roche, Inc.). In this "all-oral"
chemotherapy program, eligible patients will receive capecitabine (Xeloda(R);
Hoffmann La Roche, Inc.) and will be randomly assigned to receive capsules of
tesetaxel or placebo. The primary endpoint of the trial is overall survival;
secondary endpoints include overall response, progression-free survival, and
safety.

"TESEGAST builds on our experience in two Phase 2a studies and more than 80
patients treated with tesetaxel as 2nd-line therapy for advanced gastric
cancer," said Dr. Loretta M. Itri, Genta's President and Chief Medical Officer.
"We are pleased with the outcome of extensive discussions with regulatory
authorities in all territories that are involved with the trial."

"Intravenous taxanes are frequently used to treat patients with advanced gastric
cancer; however, allergic reactions occur frequently and neutropenia is common,"
said Dr. Jaffer Ajani, Professor of Medicine at the M.D. Anderson Cancer Center,
Houston, TX, who is the global Principal Investigator for TESEGAST. "Our Phase 2
experience as 2nd-line therapy for patients with advanced gastric cancer showed
that the response rate from tesetaxel has equaled or exceeded that of docetaxel
in this patient population. I am excited to initiate the first randomized trial
to observe whether the promising response rate to tesetaxel will translate into
a survival benefit for our patients."

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product
portfolio that is focused on delivering innovative products for the treatment of
patients with cancer. The Company is developing tesetaxel, a novel, orally
absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel.
As the leading oral taxane in clinical development, tesetaxel has been evaluated
in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials.
The Company has announced that gastric (stomach) cancer will be the lead
indication for registration. Genta is exclusively marketing Ganite(R) (gallium
nitrate injection) in the U.S, which is indicated for treatment of symptomatic
patients with cancer-related hypercalcemia that is resistant to hydration. The
Company has developed proprietary oral formulations of the active ingredient in
Ganite(R) that are being evaluated as potential treatments for diseases
associated with accelerated bone loss. For more information about Genta, please
visit our website at: www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to
business conducted by Genta Incorporated. By their nature, forward-looking
statements and forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future. Such
forward-looking statements include those that express plan, anticipation,
intent, contingency, goals, targets, or future developments and/or otherwise are
not statements of historical fact. The words "potentially," "anticipates,"
"projects," "expects," "could," "calls for," and similar expressions also
identify forward-looking statements. The Company does not undertake to update
any forward-looking statements. Factors that could affect actual results
include, without limitation, risks associated with:





-- the Company's ability to obtain necessary regulatory approval for its

product candidates from regulatory agencies, such as the U.S. Food and

Drug Administration and the European Medicines Agency;

-- the safety and efficacy of the Company's products or product candidates;

-- the commencement and completion of any clinical trials;

-- the Company's assessment of its clinical trials;

-- the Company's ability to develop, manufacture, license, or sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute any license

and collaborative agreements;

-- the adequacy of the Company's capital resources and cash flow

projections, the Company's ability to obtain sufficient financing to

maintain the Company's planned operations, or the risk of bankruptcy;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's most recent

Annual Report on Form 10-K and Quarterly Report on Form 10-Q.





There are a number of factors that could cause actual results and developments
to differ materially. For a discussion of those risks and uncertainties, please
see the Company's most recent Annual Report on Form 10-K and its most recent
quarterly report on Form 10-Q.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Genta Incorporated


By Staff

CONTACT: CONTACT: Genta Investor Relations

info@genta.com

908-286-3980




(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

-0-

Chembio Diagnostics Reports First Quarter 2012 Financial Results
Record
Product Sales More Than Double Over Prior Year; Conference Call Begins at 10:00
a.m. Eastern Time Today


MEDFORD, NY, May 08, 2012 (MARKETWIRE via COMTEX) -- Chembio Diagnostics, Inc.
(OTCQB: CEMI) (PINKSHEETS: CEMI), a leader in point-of-care diagnostic tests for
infectious diseases, today reported financial results for the three months ended
March 31, 2012.

Financial highlights for the first quarter of 2012 include the following (all
comparisons are with the first quarter of 2011):





-- Total revenues of $6.65 million, up 83% compared with $3.64 million

-- Product sales of $6.36 million, up 111% compared with $3.02 million

-- Operating income of $720,000, compared with an operating loss of

$139,000

-- Net income of $433,000 or $0.01 per diluted share, compared with a net

loss of $142,000 or $0.00 per diluted share



Commenting on the Company's strong quarterly performance, Lawrence Siebert,
Chembio's Chief Executive Officer, said, "2012 has gotten off to a very strong
start with record product sales more than doubling compared with the prior year.
These gains were led by increased purchase orders from the Oswaldo Cruz
Foundation (FIOCRUZ), our license and technology transfer partner in Brazil, and
from continued strong demand for our rapid HIV tests in the U.S. We remain
confident about the financial outlook for 2012, which we believe will include
record revenues and operating income.

"We were pleased to complete enrollment in our 3,000-patient clinical trial for
our DPP(R) HIV 1/2 Assay in mid-April. This important and versatile product is a
rapid point-of-care test for the detection of antibodies to HIV 1 and 2 in oral
fluid, finger-stick whole blood, venous whole blood, serum or plasma. The test
provides a simple 'reactive/non-reactive' result intended to be used in the
preliminary diagnosis of patients with HIV in point-of-care settings such as
public health and other clinics, hospital emergency rooms and physician offices.
We have previously filed the first two modules of our Pre-Marketing Approval
(PMA) application with the U.S. Food and Drug Administration (FDA) and expect to
file the third and final module by the end of the second quarter. We have
confidence that this product will meet the required performance on all sample
matrices.

"With more than 1.1 million Americans estimated to be living with HIV and
approximately 20% of them unaware they are infected with the virus, rapid HIV
tests are playing a critical role in the U.S., as they have globally, to help
identify those with HIV and to prevent disease transmission. Pending FDA
approval, our DPP HIV 1/2 assay test, with its ability to test oral fluids,
should provide a significant market opportunity for Chembio in the coming years
and gives us an opportunity to brand our DPP product line in the U.S.

"We look forward to continued growth of our DPP product line in Brazil by
FIOCRUZ and expect this collaboration to drive revenue growth throughout 2012,"
concluded Mr. Siebert.

First Quarter Results

Total revenues for the first quarter of 2012 were $6.65 million, up 83% compared
with total revenues of $3.64 million for the first quarter of 2011. Product
sales increased 111% to $6.36 million from $3.02 million in the prior-year
period, and exceeded product sales for the first six months of 2011 by $374,000.
Research and development (R&D), milestone, grant and royalty revenues for the
first quarter of 2012 decreased to $290,000 from $621,000 in the same period of
2011.

Gross profit increased 73% to $3.3 million in the 2012 first quarter compared
with $1.93 million in the 2011 first quarter due to higher product revenue and
changes in product mix, partially offset by lower R&D, licensing and royalty
revenues. Product gross profit for the first quarter of 2012 increased 133% to
$3.04 million, compared with $1.31 million for the comparable period in 2011.

R&D expenses were $1.38 million in the first quarter of 2012 and $1.29 million
in the prior year. The 2012 first quarter included $191,000 of clinical trial
expenses which were incurred in 2011 and were not invoiced until April of 2012.

For the three months ended March 31, 2012, selling, general and administrative
expenses increased to $1.23 million from $775,000 in the prior year, largely due
to higher commissions on DPP product sales to Brazil, as well as to higher wages
and stock-based compensation.

Operating income for the first quarter of 2012 was $720,000, compared with an
operating loss of $139,000 for the first quarter of 2011.

Net income for the first quarter of 2012 was $433,000 or $0.01 per diluted
share, compared with a net loss of $142,000 or $0.00 per share for the
comparable period in 2011. The 2012 first quarter net income included $285,000
in income tax provision, which reflects approximately the amount of income taxes
that would be attributable to the Company's profit for the quarter if the
Company did not have an operating loss carryforward to offset income taxes
payable.

Balance Sheet Highlights

The Company had cash of $2.95 million as of March 31, 2012, compared with $3.01
million as of December 31, 2011.

Conference Call

Chembio has scheduled a conference call and webcast for 10:00 a.m. Eastern time
today. To participate on the call, please dial (877) 407-0778 from the U.S. or
(201) 689-8565 from outside the U.S. In addition, following the completion of
the call, a telephone replay will be accessible until March 15, 2012 at 11:59
p.m. Eastern time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from
outside the U.S. and entering reservation account number 286 and conference ID
#: 393134. The conference call may also be accessed via the internet at
http://www.investorcalendar.com/IC/CEPage.asp?ID=167559. An archive of the
webcast will be available for 90 days on the Company's website at
www.chembio.com.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing point-of-care testing market.
Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the
U.S. by Alere North America, Inc. Chembio markets its HIV STAT-PAK(R) line of
rapid HIV tests internationally to government and donor-funded programs directly
and through distributors. Chembio has developed a patented point-of-care test
platform technology, the Dual Path Platform (DPP(R)) technology, which has
significant advantages over lateral-flow technologies. This technology is
providing Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP(R). Headquartered in
Medford, NY, with approximately 160 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking
statements within the meaning of the Securities Act of 1933, as amended.
Forward-looking statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements are
estimates only, as the Company has not completed the preparation of its
financial statements for those periods, nor has its auditor completed a review
or audit of those results. Actual revenue may differ materially from those
anticipated in this press release. Such statements reflect management's current
views, are based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing, to obtain regulatory approvals in a
timely manner and the demand for Chembio's products. Chembio undertakes no
obligation to publicly update these forward-looking statements to reflect events
or circumstances that occur after the date hereof or to reflect any change in
Chembio's expectations with regard to these forward-looking statements or the
occurrence of unanticipated events. Factors that may impact Chembio's success
are more fully disclosed in Chembio's most recent public filings with the U.S.
Securities and Exchange Commission.







Chembio Diagnostics, Inc. & Subsidiary

Summary of Condensed Consoldidated Results of Operations



For the three months ended

---------------------------

March 31, March 31,

2012 2011

------------- -------------

Net product sales $ 6,363,152 $ 3,015,063



License and royalty revenue - 28,854



R&D, milestone and grant revenue 290,100 591,764

------------- -------------



TOTAL REVENUES $ 6,653,252 $ 3,635,681



GROSS MARGIN $ 3,332,864 $ 1,926,342



Research and development expenses $ 1,379,131 $ 1,290,142



Selling, general and administrative expenses $ 1,233,968 $ 775,371



INCOME (LOSS) FROM OPERATIONS $ 719,765 $ (139,171)



Income tax provision $ 285,400 $ -



NET INCOME (LOSS) $ 433,443 $ (142,297)



Basic net income per share $ 0.01 $ (0.00)



Diluted net income per share $ 0.01 $ (0.00)



Weighted average number of shares outstanding,

basic 63,474,580 62,284,772



Weighted average number of shares outstanding,

diluted 68,098,858 62,284,772







Chembio Diagnostics, Inc. & Subsidiary

Summary of Condensed Consolidated Balance Sheets



March 31, December 31,

2012 2011

------------- -------------



CURRENT ASSETS:

Cash and cash equivalents $ 2,954,276 $ 3,010,954

Accounts receivable, net of allowance for

doubtful accounts of $125,000 and $30,000 for

2012 and 2011, respectively 3,616,720 2,998,449

Inventories 2,706,676 2,300,286

Prepaid expenses and other current assets 755,082 681,893

------------- -------------

TOTAL CURRENT ASSETS 10,032,754 8,991,582



FIXED ASSETS, net of accumulated depreciation 1,118,989 1,062,276



OTHER ASSETS

Deferred tax asset, net of valuation allowance 4,492,763 4,749,622

License agreements and other assets 715,290 682,264

------------- -------------



$ 16,359,796 $ 15,485,744

============= =============



TOTAL CURRENT LIABILITIES $ 3,133,399 $ 2,857,626



TOTAL OTHER LIABILITIES 120,937 133,484

------------- -------------



TOTAL LIABILITIES 3,254,336 2,991,110



TOTAL STOCKHOLDERS' EQUITY 13,105,460 12,494,634

------------- -------------



$ 16,359,796 $ 15,485,744

============= =============







Chembio Diagnostics, Inc. & Subsidiary

Summary of Condensed Consolidated Cash Flow



For the three months ended

----------------------------

March 31, March 31,

2012 2011

------------- -------------



Net cash provided by operating activities $ 149,226 $ 1,560,142

Net cash used in investing activities (223,716) (46,358)

Net cash provided by (used in) financing

activities 17,812 (853,032)

------------- -------------

(DECREASE) INCREASE IN CASH AND CASH

EQUIVALENTS $ (56,678) $ 660,752

============= =============










Contacts:

Chembio Diagnostics

Susan Norcott

(631) 924-1135, ext. 125

snorcott@chembio.com



LHA

Anne Marie Fields

(212) 838-3777

AFields@lhai.com

@LHA_IR_PR





SOURCE: Chembio Diagnostics, Inc.




CONTACT: mailto:snorcott@chembio.com

mailto:AFields@lhai.com




Copyright 2012 Marketwire, Inc., All rights reserved.

-0-




SUBJECT CODE: Medical and Healthcare:Healthcare

Medical and Healthcare:Alternative

Medical and Healthcare:Medical Devices

Pharmaceuticals and Biotech:Trials

Pharmaceuticals and Biotech:Biotech

Pharmaceuticals and Biotech:Drugs

Pharmaceuticals and Biotech:Equipment and Supplies

Medical and Healthcare:Surgery and Treatments

MMT/MAUXF..Mart Annnounces a 16% Increase in 2011 Year End Proved Reserves


CALGARY, ALBERTA, May 8, 2012 (Marketwire via COMTEX) -- Mart Resources, Inc.
(TSX VENTURE:MMT) ("Mart" or the "Company") is pleased to announce the results
of independent reserve evaluations of the Company's reserves effective December
31, 2011 and the filing on SEDAR of its Statement of Reserves Data and Other Oil
and Gas Information as prescribed by National Instrument 51-101 - Standards of
Disclosure for Oil and Gas Activities.

2011 Highlights:

December 31, 2011 Reserve Highlights of Mart's Interest:







-- Mart's total gross proved ("1P") oil reserves in the Umusadege field

increased 16% to approximately 11.2 million barrels of oil ("bbls")

compared to 9.6 million bbls at December 31, 2010;

-- Mart's total gross proved plus probable ("2P") oil reserves in the

Umusadege field increased 15% to approximately 14.9 million bbls

compared to 12.9 million bbls at December 31, 2010;

-- Mart's total gross proved plus probable plus possible ("3P") oil

reserves in the Umusadege field increased 9% to approximately 22.0

million bbls compared to 20.1 million at December 31, 2010;

-- Mart's net present value before tax of future net revenue, discounted at

10%, from the 2P Umusadege field reserves as at December 31, 2011 was

US$782.4 million (compared to US$536 million as at December 31, 2010).





The 1P, 2P and 3P reserves figures and net present value of future net revenue
contained in the 2011 Highlights provided above, have been calculated in
compliance with Canadian National Instrument 51-101 - Standards of Disclosure
for Oil and Gas Activities ("NI 51- 101") and the Canadian Oil and Gas
Evaluation Handbook ("COGEH") and have been derived from the data contained in
the Company's Form NI 51-101F1 - Statement of Reserves Data and Other Oil and
Gas Information dated April 30, 2012 (effective December 31, 2011) filed on
SEDAR (www.sedar.com) and on Mart's website, www.martresources.com.

The December 31, 2011 year-end reserves evaluation report for the Umusadege
field was prepared by RPS Energy (the "2011 RPS Report") and includes an
evaluation of the vertical section of the UMU-9 well discoveries down to the XIV
sand only, as drilling and evaluation of the deviated section was still ongoing
as at December 31, 2011. The full well test data, lab results and analyses of
the deviated section of the well are now available, and Mart has retained RPS
Energy to prepare an update to the 2011 RPS Report that will include an
evaluation of the deeper sand discoveries.

Wade Cherwayko, Chairman and CEO of Mart Resources, Inc., said "We are very
pleased with the increases to Mart's reserves and continued strong production in
2011 which was obtained through successful development and appraisal of new
reserves and successful management of existing reserves. In 2012, Mart and our
co-venturers are focused on continuing to grow reserves and production through
development and appraisal drilling and reservoir management in the Umusadege
field."

The following table summarizes Mart's 2011 year-end gross and net after royalty
reserves. Also shown in the following table, for comparative purposes, are
Mart's net after royalty reserves for year-end 2010.

Summary of Oil and Gas Reserves Using Forecast Prices and Costs







Mart Net

Mart Gross Reserves(1)(3) Reserves(1)(3)

12/31/11 12/31/11

Light and Medium Oil (mbbl) (mbbl)

----------------------------------------------------------------------------

Reserves Category(4) Umusadege Qua Ibo(5) Umusadege Qua Ibo(5)

--------------------------------------------------------

Proved

Developed 2,680 - 2,572 -

Producing

Developed Non- - - - -

Producing

- -

Undeveloped 8,480 7,898

Total Proved 11,160 - 10,470 -

Total Probable 3,736 9,754 3,395 8,960

Total Proved plus

Probable 14,896 9,754 13,865 8,960

Total Possible (6) 7,075 19,908 6,300 18,590

Total Proved plus

Probable plus

Possible (6) 21,971 29,662 20,165 27,550



Mart Gross Reserves(2)(3)

12/31/10

Light and Medium Oil (mbbl)

------------------------------------------------

Reserves Category(4) Umusadege Qua Ibo(5)

----------------------------

Proved

Developed 2,105 -

Producing

Developed Non- - -

Producing

-

Undeveloped 7,527

Total Proved 9,632 -

Total Probable 3,315 9,745

Total Proved plus

Probable 12,947 9,745

Total Possible (6) 7,188 19,951

Total Proved plus

Probable plus

Possible (6) 20,135 29,696





The net present values of Mart's reserves as at December 31, 2011 before and
after tax, discounted at 10% are as follows:







Before Tax - Net Bbls

NPV at 10% discount per bbl:

Before tax (in US$ millions) Umusadege (1) Qua Ibo(1)(5) Total

---------------------------------------------

Total Proved $ 584.1 $ 0.0 $ 584.1

Total Probable $ 198.4 $ 266.7 $ 465.1

---------------------------------------------

Total Proved plus Probable $ 782.4 $ 266.7 $ 1,049.1

---------------------------------------------

After Tax - Net Bbls

NPV at 10% discount per bbl:

After tax (in US$ millions) Umusadege (1) Qua Ibo (1)(5) Total

---------------------------------------------

Total Proved $ 445.8 $ 0.0 $ 445.8

Total Probable $ 129.1 $ 105.7 $ 234.8

---------------------------------------------

Total Proved plus Probable $ 574.9 $ 105.7 $ 680.6

---------------------------------------------





Notes:







1. The information contained herein for the Umusadege field has been

derived from a reserve report dated April 10, 2012 (effective as of

December 31, 2011) prepared by RPS Energy Canada Inc. ("RPS"). The

information contained herein for the Qua Ibo field has been derived from

a reserve report dated April 9, 2012 (effective December 31, 2011)

prepared by Chapman Petroleum Engineering Ltd. ("Chapman").

2. The information contained herein for the Umusadege field has been

derived from a reserve report dated April 19, 2011 (effective as of

December 31, 2010) prepared by RPS. The information contained herein for

the Qua Ibo field has been derived from a reserve report dated April 4,

2011 (effective December 31, 2009) prepared by Chapman.

3. Gross Reserves means Mart's working interest share of total field

reserves after deducting reserves volumes owned by others but before

deducting reserves attributable to government and third party royalties

and income taxes or their equivalent. Net Reserves means Mart's working

interest share of total field reserves after deducting reserves volumes

owned by others and after deducting reserves attributable to government

and third party royalties but before income taxes or their equivalent.

4. All reserves definitions utilized herein are as set out in the Canadian

Oil and Gas Evaluation Handbook ("COGEH").

5. As at December 31, 2010, Mart continued to hold a participation interest

in the Qua Ibo field. Subsequent to December 31, 2011, the Company

entered into an agreement pursuant to which Mart and Network Exploration

& Production Nigeria Limited have amicably terminated Mart's

participating interest in the Qua Ibo field. Under the terms of the

agreement, Network has assumed responsibility for outstanding

liabilities of approximately US$3.2 million for the Qua Ibo field and

has paid Mart a US$1.0 million termination fee.

6. Possible reserves are those additional reserves that are less certain to

be recovered than probable reserves. There is a 10% probability that the

quantities actually recovered will equal or exceed the sum of proved

plus probable plus possible reserves.

7. The estimates of reserves and future net revenue for individual

properties may not reflect the same confidence level as estimates of

reserves and future net revenue for all properties, due to the effects

of aggregation.

8. Due to rounding, certain columns may not add exactly.





Grant of Stock Options

Mart also announces that it has granted an aggregate of 6,590,000 options, of
which 4,350,000 options were granted to directors or officers of Mart. Each
option represents the right to purchase one common share of Mart at an exercise
price of $1.04 per share for a period of five years.

ABOUT MART RESOURCES:

Mart Resources, Inc. is an independent, international petroleum company focused
on drilling, developing and producing oil and gas from proven petroleum
properties in Nigeria, West Africa. The Company is currently producing and
developing the Umusadege field along with Midwestern Oil and Gas Co. Plc (the
Operator of the field) and SunTrust Oil Ltd. Mart also owns a land drilling rig,
has strong local relationships and experience and is evaluating additional
proven undeveloped opportunities in Nigeria.

INVESTOR RELATIONS:

Investors are also welcome to contact one of the following investor relations
specialists for all corporate updates and investor inquiries:

FronTier Consulting Ltd.

Mart toll free # 1-888-875-7485

Attn: Sam Grier or Caleb Gilani

Email: inquiries@martresources.com

Information Regarding Reserves and Net Present Value of Future Net Revenues

All information contained in this press release regarding reserves and the net
present value of future net revenue has been derived from the Company's Form
51-101 F1-Statement of Reserves Data and Other Oil and Gas Information for the
year ended December 31, 2011 ("Statement of Reserves Data") which report, along
with the Form 51-101F2-Report on Reserves Data and Form 51-101F3-Report of
Management and Directors on Reserves Data and Other Information are available
for review at www.sedar.com and on the Company's website at
www.martresources.com.

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking
statements" as such term is used in applicable Canadian and US securities laws.
Any statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, assumptions or future
events or are not statements of historical fact should be viewed as
"forward-looking statements". These statements relate to analyses and other
information that are based upon forecasts of future results, estimates of
amounts not yet determinable and assumptions of management. Such forward looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements.

In particular, information regarding the reserve estimates attributable to
Mart's oil and gas properties should be considered forward looking statements,
as they involve the implied assessment, based on certain estimates and
assumptions, that the reserves described exist in the quantities predicted or
estimated and that the reserves can be profitably produced in the future.
Readers are referred to the heading "Forward Looking Statements" in the
Company's Statement of Reserves Data for a more detailed discussion of risks
associated with forward looking statements. In addition, past production
performance, sales volumes and prices from Mart's Umusadege field are not
necessarily indicative of future performance, sales volumes and prices.

There can be no assurance that such forward-looking statements will prove to be
accurate as actual results and future events could vary or differ materially
from those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements contained in this news release. The
forward-looking statements contained herein are expressly qualified by this
cautionary statement.

Forward-looking statements are made based on management's beliefs, estimates and
opinions on the date the statements are made and the Company undertakes no
obligation to update forward-looking statements and if these beliefs, estimates
and opinions or other circumstances should change, except as required by
applicable law.

SOURCE: Mart Resources, Inc.



CONTACT: Mart Resources, Inc. - London, England

Wade Cherwayko

+44 207 351 7937

Wade@martresources.com

Mart Resources, Inc.

Investor Relations

Toll Free: 1-888-875-7485

www.martresources.com




Copyright (C) 2012 Marketwire. All rights reserved.

-0-




INDUSTRY KEYWORD: Energy and Utilities\Oil and Gas

SUBJECT CODE: OIL/GAS DRILLING RESULTS

.0019...Looks like about to take off

QualityStocks News - Viking Systems Posts Q1 Results, Business Update


Scottsdale, Arizona, May 04, 2012 (PRWeb.com via COMTEX) -- QualityStocks would
like to highlight Viking Systems, Inc., a publicly traded developer,
manufacturer and marketer of 3D and 2D visualization solutions for complex
minimally invasive surgery. Viking actively markets and sells the only stand
alone, FDA cleared, cost-effective 3D system for use in minimally invasive
laparoscopic surgery. Viking partners with medical device companies and
healthcare facilities to provide surgeons with proprietary visualization systems
enabling minimally invasive surgical procedures, which reduce patient trauma and
recovery time. Viking, through its OEM products business, also designs and
manufactures surgical vision systems and components for several leading medical
instrument companies worldwide.

In the company's news yesterday,

Viking Systems posted its first-quarter results for the three months ended March
31, 2012.

Viking reports a 13 percent year-over-year increase in 2012 first-quarter
revenues to $3.5 million, an increase of 61 percent compared to fourth quarter
2011 revenues.

Gross profit for the quarter was $959,000, an increase of 47 percent
year-over-year, and an increase of 138 percent compared to the fourth quarter of
2011.

Net loss for the quarter was $401,000, compared with a loss of $446,000 in the
first quarter of 2011 and a loss of $1.0 million in the fourth quarter of 2011.

Viking also provided a business update, noting that as of March 31, 2012, the
company has sold a total of 90 of its 3DHD Vision Systems since the product was
launched in the fourth quarter of 2010.

It sold seven clinical systems during the first quarter of 2012, bringing the
total number of clinical systems sold in the U.S. to 11. The company also added
two new distribution partners in the first quarter, Keir Surgical in Canada and
Neo Medical Systems covering Belgium and Luxemburg.

"We are pleased to be able to report that the first quarter of 2012 was a record
quarter for total sales and placements of our 3DHD Vision Systems. Both total
3DHD systems, and more importantly, placements of clinical systems, meaning non
demonstration systems, were at record levels," Jed Kennedy, president and CEO of
Viking Systems stated in the press release. "While placement of demonstration
systems is important in creating the selling infrastructure needed to place
systems in hospitals, we believe we have reached the transition point where
clinical systems sales will consistently exceed demo systems placements. We also
believe that placement of clinical systems will help to stimulate demand from
new customers as they come to see the benefits being realized by the early
adopters of our technology."

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects
data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into
one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging
public companies with their investor communication efforts and connecting
subscribers with companies that have huge potential to succeed in the short and
long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit
http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit
http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit
http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website:
http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All forward-looking statements are
inherently uncertain as they are based on current expectations and assumptions
concerning future events or future performance of the company. Readers are
cautioned not to place undue reliance on these forward-looking statements, which
are only predictions and speak only as of the date hereof. Risks and
uncertainties applicable to the company and its business could cause the
company's actual results to differ materially from those indicated in any
forward-looking statements.

Read the full story at http://www.prweb.com/releases/2012/5/prweb9475125.htm



URL: PRWeb.com


PRWEB.COM Newswire

-0-

<<<Mr. Love concluded, "In addition to more stock dividends, there is a legitimate
plan to issue cash dividends upon conclusion of certain transactions. We do not
plan to issue regular cash dividends, but we do expect to make distributions
from time to time in the future." >>>

olos Endoscopy to Finalize ISO 13485 Certification and CE Mark
Initiative with Expert Resource for Endoscopic Instruments


BOSTON, May 4, 2012 /PRNewswire via COMTEX/ -- Solos Endoscopy, Inc. (OTCPK:
SNDY) is pleased to announce that the Company has agreed to finalize and
complete its ISO 13485 Certification and CE Mark initiative with Expert
Resource. Expert Resource will continue to provide consulting services in
support of the Company's ISO 13485 quality management system (QMS) initiative.

Solos previously retained Expert Resource and completed Phase I of IV of its
requirements for its ISO 13485 QMS initiative. Solos had to temporarily suspend
its efforts due to unanticipated increased costs, partially attributable to
changes in documentation required by the International Organization for
Standardization (ISO); as a result, the Company exceeded its maximum budgetary
constraints. However currently, Solos has been able to utilize its equity,
increase its authorized capital, and has made all the necessary financial
arrangements to complete the certification. All Solos Endoscopy instruments are
FDA approved, but with ISO 13485 Certification they will also all receive the CE
Mark required for international sales.

Expert Resource will provide comprehensive consulting, training and document
preparation for Solos Endoscopy to create a quality management system that meets
the requirements of the ISO 13485 standard. Compliance with ISO 13485 is a major
step in obtaining the CE Mark and the permission to sell medical devices in
Europe and Canada.

Expert Resource is an international consulting and training firm specializing in
business improvement initiatives. ER helps medical device and medical laboratory
companies implement ISO 13485, ISO 15189, ISO 14971, or GMP quality systems,
obtain the CE Mark, submit FDA 510(k) applications, assist with clinical trials,
and more. For more information on Expert Resource, visit www.expertresource.net.

According to Reportlinker, the demand for endoscope services is increasing due
to an increase in the aging and chronically ill population worldwide.
Advancements in endoscopic technologies and inclusion of various types of
lighting sources, video cameras, real-time conversion of data into
three-dimensional images are also driving this market. Endoscopy procedures have
become highly effective in the diagnosis, treatment, and management of cancer
patients. Many now consider endoscopy to have become the gold standard for
cancer diagnosis and treatment, as well as for many other medical conditions.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to
develop and market high quality and innovative instruments for the screening,
diagnosis, treatment and management of medical conditions. Additional
information on its FDA approved products is available on the Company's website
at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 27E of the Securities
Act of 1934. Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results may differ materially from that projected or suggested herein due to
certain risks and uncertainties including, without limitation, ability to obtain
financing and regulatory and shareholder approval for anticipated actions.

CONTACT:

AMANDA SEGERSTENRSEGERSTEN@SOLOSENDOSCOPY.COM

SOURCE Solos Endoscopy, Inc.



www.prnewswire.com


Copyright (C) 2012 PR Newswire. All rights reserved

-0-

NEWS....LIG Assets, Inc. Announces Plans to Issue More Stock Dividends; Selects
New Transfer Agent to Distribute SuiteMagic Shares


DALLAS, May 4, 2012 /PRNewswire via COMTEX/ -- LIG Assets, Inc. (LIGA.PK)
announces plans to issue at least two more stock dividends, and that it has
selected a transfer agent to distribute the recently announced stock dividend of
SuiteMagic shares. Globex Transfer, LLC (www.globextransfer.com) of Deltona, FL
is registered as a Stock Transfer Agent with the Securities and Exchange
Commission and is a member of The Securities Transfer Association which is
available only to stock transfer agents. SuiteMagic is expected to go public
through an S-1 filing later this year.

Although the primary focus of LIG Assets is in real estate transactions and
income producing properties, the Company has a variety of other business
interests evidenced by its recent stock dividend paid in SuiteMagic. LIG Assets
has identified at least two other divisions it would prefer to spin off, operate
separately, and issue stock as dividends to its shareholders in LIGA over the
next 12 to 18 months.

LIG Assets always plans to retain a large percentage ownership of the separate
operating companies. In the case of SuiteMagic, LIG Assets will retain about 45%
ownership of SuiteMagic even after the stock dividend is distributed.

Jeff Love, CEO of LIG Assets stated, "Our business plans are centered on
building our asset base and balance sheet. We are involved in a variety of
businesses, and some deserve to operate independent of the core for a variety of
reasons." He continued, "It makes sense to spin these off as separate trading
entities not only to benefit our shareholders, but provide to provide each
entity more focus and autonomy."

Mr. Love concluded, "In addition to more stock dividends, there is a legitimate
plan to issue cash dividends upon conclusion of certain transactions. We do not
plan to issue regular cash dividends, but we do expect to make distributions
from time to time in the future."

About LIG Assets, Inc.

LIG Assets, Inc., based in Dallas, TX, is a multi-faceted worldwide investment
company that focuses on real estate, technology, commodities, and the oil and
gas sectors of the economy. We are a proactive company that is committed to
providing opportunities in all structures of the economy and are always
welcoming new opportunities. LIG Assets, Inc. trades on the pink sheets under
the ticker symbol "LIGA".

For additional information, please visit LIG Assets corporate website:
www.ligassetsinc.net.

Forward-Looking Statements

This press release may contain forward-looking statements. The words "believe,"
"expect," "should," "intend," "estimate," "projects," variations of such words
and similar expressions identify forward-looking statements, but their absence
does not mean that a statement is not a forward-looking statement. These
forward-looking statements are based upon the Company's current expectations and
are subject to a number of risks, uncertainties and assumptions. The Company
undertakes no obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise. Among the important
factors that could cause actual results to differ significantly from those
expressed or implied by such forward-looking statements are risks that are
detailed in the Company's filings, which are on file with the U.S. Securities
and Exchange Commission (SEC).

Contact Information:LIG Assets, Inc.(214) 760-1000

Investor Relations Contact: Bravo International ServicesLarry K. Davis (250)
595-7714

SOURCE LIG Assets, Inc.



www.prnewswire.com


Copyright (C) 2012 PR Newswire. All rights reserved

-0-

Energy Edge Announces Distribution Agreement with Energy Control
Equipment


BRIDGEWATER, N.J., May 2, 2012 /PRNewswire via COMTEX/ -- Energy Edge
Technologies Corporation (OTCBB: EEDG) has entered into a national
distributorship agreement with Energy Control Equipment, Inc. Energy Edge will
immediately begin offering Energy Control's proven new energy saver, the
"Frigitek", as part of its comprehensive energy projects for building owners,
developers, architects, contractors, and businesses looking to enhance their
commercial refrigeration efficiencies and dramatically reduce costs.

The Frigitek saves significant amounts of energy and cost in commercial
refrigeration systems. It features two-speed operation for evaporator fans -
high speed during cooling, and low speed when not cooling. It is designed to be
easily and cost effectively retrofitted into existing systems and provides for
even higher savings, rebates and tax incentives for Energy Edge customers. In
fact, the Frigitek uses less than half the energy of typical motors and reduces
heat load approximately 75-80% which results in additional utility reduction for
commercial refrigeration, which is notoriously energy intensive.

"Energy Edge is a perfect partner for us," said Al Linder, President of Energy
Control Equipment. "Not only does EEDG represent a tremendous new outlet for our
products, but our new partnership gives all of our existing and future customers
the opportunity benefit from Energy Edge's expanded suite of energy engineering,
energy management, and consulting services."

The Energy Edge team is comprised of industry leading Ph.D.'s, Professional
Engineers and Energy Experts with over 250 years of combined industry
experience. For a complete list of EEDG's services, please visit
www.energyet.com.

Contact:Sandy Masciasmascia@energyet.com 1-888-729-5722

Forward Looking Statements This release contains statements, which may
constitute "forward-looking statements" within the meaning of the Securities Act
of 1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking statements.
Important factors currently known to management that could cause actual results
to differ materially from those in forward-looking statements include
fluctuation of operating results, the ability to compete successfully, and the
ability to complete before-mentioned transactions. The Company undertakes no
obligation to update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events, or changes to future
operating results.

SOURCE Energy Edge Technologies Corporation



www.prnewswire.com

VSTI..http://ih.advfn.com/p.php?pid=nmona&article=52250729

NEWS http://finance.yahoo.com/news/union-equity-inc-announces-filing-162700144.html

MAUXF/MMT Mart Announces Record Financial and Operating Results for the Year Ended
December 31, 2011


CALGARY, ALBERTA, May 1, 2012 (Marketwire via COMTEX) -- Mart Resources, Inc.
(TSX VENTURE:MMT) ("Mart" or the "Company") is pleased to announce its financial
and operating results for the year ended December 31, 2011 (all amounts in
Canadian dollars unless noted):

YEAR ENDED DECEMBER 31, 2011



-- Net income for the year ended December 31, 2011 totaled $71.8 million

($0.214 per share), compared to net income of $8.7 million ($0.026 per

share) for the year ended December 31, 2010.



-- Funds flow from production operations were $144.1 million ($0.429 per

share) for the year ended December 31, 2011 compared to $48.2 million

($0.144 per share) for the year ended December 31, 2010 (see note (1)

regarding non-IFRS measures under the table below).



-- The average price received by Mart for oil in 2011 was USD $103.21 per

barrel of oil ("bbl") (approximately CDN $102.08 per bbl), compared to

USD $81.70 per bbl (approximately CDN $84.07 per bbl) in 2010.



-- Mart's share of Umusadege field oil produced and sold for the year ended

December 31, 2011 was 1,803,459 bbls compared to 732,101 bbls for the

year ended December 31, 2010. The main reason for the production

increase was the additions of UMU-8, UMU-7, and UMU-6 wells coupled with

an increase in cost oil recovery from 67% to an average rate of 71%

during the year.



-- Mart's share of proved Umusadege gross oil reserves after tax increased

by 15% to 10.5 million bbls compared to 9.1 million bbls in 2010.



-- Mart's share of proved plus probable Umusadege gross oil reserves after

tax increased by 16% to 13.9 million bbls compared to 12.0 million bbls

in 2010.



-- In 2011 the Umusadege field had a total of 50 shut-in days due mainly to

export pipeline disruptions, and to maintenance and modification of

production facilities, compared to a total of 92 shut-in days in 2010.



-- Mart's average daily oil production for 2011 was 4,941 barrels oil per

day ("bopd") compared to 2,005 bopd in 2010.





THREE MONTH PERIOD ENDED DECEMBER 31, 2011




-- Net income for Q411 was $21.1 million ($0.063 per share) compared to net

income of $2.1 million ($0.006 per share) for Q410.



-- Funds flow from production operations of $36.9 million ($0.110 per

share) for Q411 compared to $6.7 million ($0.020 per share) for Q410

(see note (1) regarding non-IFRS measures under the table below).



-- The average price received by Mart for oil in Q411 was USD $109.69 per

bbl (approximately CDN $108.49 per bbl) compared to USD $89.21 (CDN

$96.86 per bbl) for Q410.



-- Mart's share of Umusadege field oil produced and sold for the three

months ended December 31, 2011 ("Q411") was 432,166 bbls compared to

104,255 bbls for the three months ended December 31, 2010 ("Q410").



-- During Q411, the Umusadege field was shut-in for a total of 17 days

(Q410 65 days) due to various disruptions in the export pipeline and

maintenance and modification of production facilities.



-- UMU-8 well started producing in December 2011 and UMU-9 well was logged

showing 260 feet of pay.



-- Mart's average daily oil production for Q411 was 4,697 bopd compared to

1,158 bopd for Q410.





FINANCIAL AND OPERATING RESULTS

The following table provides a summary of Mart's selected financial and
operating results for the three month period ended and the years ended December
31, 2011 and 2010:







3 months 3 months 12 months 12 months

(CDN$) ended ended ended ended

Dec 31, Dec 31, Dec 31, Dec 31,

2011 2010 2011 2010

-----------------------------------------------------

Mart's share of the Umusadege

Field:

Barrels of oil produced

and sold 432,166 104,255 1,803,459 732,101

Average sales price per

barrel $ 108.485 $ 96.864 $ 102.081 $ 84.073

Mart's percentage share

of total Umusadege oil

produced and sold

during the period 77% 76% 71% 67%

Mart's share of

petroleum sales after

royalties 40,945,141 9,027,052 162,431,467 56,524,797

Funds flow from

production operations

(1) 36,927,682 6,677,197 144,129,393 48,235,615



Basic $ 0.110 $ 0.020 $ 0.429 $ 0.144



Net income 21,123,991 $ 2,127,266 71,801,346 8,698,547

Per share - basic $ 0.063 $ 0.006 $ 0.214 $ 0.026

Per share - diluted $ 0.061 $ 0.006 $ 0.209 $ 0.025



Total assets 198,021,112 118,766,739 198,021,112 118,766,739

Total bank debt Nil 5,627,778 Nil 5,627,778



Shares outstanding - end of period:



Basic 336,084,275 335,548,201 336,084,275 335,548,201

Diluted 344,318,066 342,184,661 344,318,066 342,184,661



Notes:



(1) Indicates non-IFRS measures. Non-IFRS measures are informative measures

commonly used in the oil and gas industry. Such measures do not conform to

IFRS and may not be comparable to those reported by other companies nor

should they be viewed as an alternative to other measures of financial

performance calculated in accordance with IFRS. For the purposes of this

table, the Company defines "Funds flow from production operations" as net

petroleum sales less royalties, community development costs and production

costs. Funds flow from production operations is intended to give a

comparative indication of the Company's net petroleum sales less production

costs as shown in the following table:



(CDN$) 3 months 3 months 12 months 12 months

ended ended ended ended

Dec 31, 2011 Dec 31, 2010 Dec 31, 2011 Dec 31, 2010

----------------------------------------------------------------------------

Petroleum sales 46,883,574 10,098,585 184,100,445 61,549,645

Less: Royalties and

community development

costs 5,938,433 1,071,533 21,668,978 5,024,848

----------------------------------------------------------------------------

Net petroleum sales 40,945,141 9,027,052 162,431,467 56,524,797

Less: Production costs 4,017,459 2,349,855 18,302,074 8,289,182

----------------------------------------------------------------------------

Funds flow from

production operations 36,927,682 6,677,197 144,129,393 48,235,615

----------------------------------------------------------------------------

----------------------------------------------------------------------------





RESERVES UPDATE:

Mart's total gross proved ("1P") oil reserves in the Umusadege field increased
16% to approximately 11.2 million bbls compared to 9.6 million bbls at December
31, 2010. Mart's total gross proved plus probable ("2P") oil reserves in the
Umusadege field increased 15% to approximately 14.9 million bbls compared to
12.9 million bbls at December 31, 2010. Mart's total gross proved plus probable
plus possible ("3P") oil reserves in the Umusadege field increased 9% to
approximately 22.0 million bbls compared to 20.1 million at December 31, 2010.

OUTLOOK AND OPERATIONS UPDATE:

The UMU-9 well was drilled to a depth of approximately 10,848 feet. The
intermediate section was drilled to 8,311 feet and indicated 260 feet of gross
oil pay from eleven sands based on open hole logs, and the lower deviated
section of the well was drilled from 8,311 feet to 10,848 feet and indicated an
additional 170 feet of gross oil pay in eight sands based on open hole logs.
This resulted in a total cumulative gross oil pay of approximately 430 feet of
19 sands encountered by the well. Nine sands were identified in the deviated
section of the UMU-9 well: three oil bearing sands (XVIa, XV1b, XVIIa) that had
been encountered in previous Umusadege wells and six new sands that were
discovered by the UMU-9 well. Detailed fluid analysis was conducted on five out
of the six new sands, and lab analysis has confirmed that four sands (XVIIb,
XVIIIa, XIX, XXb) contain light oil and condensate and one sand (XVIIIB)
contains gas condensate. The remaining four sands did not have fluid analysis
conducted, however open hole logs indicated the presence of hydrocarbons.

Completion and testing operations were conducted on the UMU-9 well in Q112. The
test of the XIV sand was conducted through a 3 1/2 inch tubing on a 32/64 inch
choke at a flowing tubing pressure of 480 psi. The well flowed 43 API gravity
oil with BS&W of 0.2% and an oil/gas ratio of approximately 90 standard cubic
feet per barrel. The 46 foot XIV sand flowed at a stabilized test rate of 4,240
bopd.

During the commingled test of the XIIIa and XIIIb sands, the well flowed 42 API
gravity oil through 3 1/2 inch tubing on a 28/64 inch choke at a flowing tubing
pressure of 350 psi. Basic sediment and water (BS&W) was 1.0% with no associated
gas. A stabilized flow rate of 2,576 bopd was recorded from the commingled 16
foot XIIIa and 15 foot XIIIb sands.

The test of the XIIa sand was conducted through the 2 7/8 inch tubing on a 30/64
inch choke at a flowing tubing pressure of 290 psi. The well flowed 35 API
gravity oil with BS&W of 0.8% with no associated gas. The 30 foot XIIa sand
flowed at a stabilized test rate of 3,600 bopd.

The test of the X sand was conducted through the 2 7/8 inch tubing on a 28/64
inch choke at a flowing tubing pressure of 160 psi. The well flowed 40 API
gravity oil with BS&W of 0.6% and an oil/gas ratio of 43 standard cubic feet per
barrel. The 10 foot X sand flowed at a stabilized test rate of 1,300 bopd.

The combined flow rate of the five sands tested in the UMU-9 well is 11,718
bopd. Reserve reports will be updated at a future date to incorporate the
results from the UMU-9 well.

To mitigate risks relating to export pipeline capacity, Mart and its
co-venturers continue to evaluate new export pipeline options to provide an
alternative for future production capacity. Mart and its co-venturers are
currently in discussion with an affiliate of Royal Dutch Shell plc, to provide
another independent export pipeline for Umusadege field production. If these
discussions result in Mart and its co-venturers gaining access to Shell's export
facilities, a new 50 kilometer pipeline will be constructed. The upgrade of the
central production facility at the Umusadege field to a design capacity of
approximately 30,000 bopd is approximately 75% completed.

Subsequent to December 31, 2011, the Company entered into an agreement pursuant
to which Mart and Network Exploration & Production Nigeria Limited have amicably
terminated Mart's participating interest in the Qua Ibo field. Under the terms
of the agreement, Network has assumed responsibility for outstanding liabilities
of approximately USD $3.2 million for the Qua Ibo field and has paid Mart a USD
$1.0 million termination fee.

CHAIRMAN'S COMMENT:

Wade Cherwayko, Chairman & CEO of Mart said, "We are very pleased to report
record financial and operating results for 2011 with $71.8 million of net
income, which amounts to $0.214 per share. This continues to demonstrate the
significance of the Umusadege field's production capacity. The Company continues
to work towards maximizing production and efficiency, and significant steps have
been taken towards building an additional export pipeline to enable us to fully
exploit the potential of the Umusadege field. Increasing total pipeline capacity
will provide the ability to substantially increase production and cash flow.
Mart has also had a substantial increase in its share of reserves at the
Umusadege field in 2011 as the direct result of continued successful drilling."

ABOUT MART RESOURCES:

Mart Resources, Inc. is an independent, international petroleum company focused
on drilling, developing and producing oil and gas from proven petroleum
properties in Nigeria, West Africa. The Company is currently producing and
developing the Umusadege field along with Midwestern Oil and Gas Co. Plc (the
Operator of the field) and SunTrust Oil Ltd. Mart also owns a land drilling rig,
has strong local relationships and experience and is evaluating additional
proven undeveloped opportunities in Nigeria.

For more information, please contact Wade Cherwayko at Mart's London, England
office # +44 207 351 7937 or e-mail: Wade@martresources.com. Additional
information regarding Mart Resources, Inc. is available on the company's website
at www.martresources.com and under the Company's profile on SEDAR at
www.sedar.com.

INVESTOR RELATIONS:

Investors are also welcome to contact one of the following investor relations
specialists for all corporate updates and investor inquiries:

FronTier Consulting Ltd.

Mart toll free # 1-888-875-7485

Attn: Sam Grier or Caleb Gilani

Email: inquiries@martresources.com

Note: Except where expressly stated otherwise, all production figures set out in
this press release, including bopd, reflect gross Umusadege field production
rather than production attributable to Mart. Mart's share of total gross
production before taxes and royalties from the Umusadege field fluctuates
between 82.5% (before capital cost recovery) and 50% (after capital cost
recovery).

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking
statements" as such term is used in applicable Canadian and US securities laws.
Any statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, assumptions or future
events or are not statements of historical fact and should be viewed as
"forward-looking statements". These statements relate to analyses and other
information that are based upon forecasts of future results, estimates of
amounts not yet determinable and assumptions of management. Such forward looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements.

In particular, statements (express or implied) contained herein or in Mart's
MD&A regarding the following should be considered forward-looking statements:
the Company's goals and growth strategy, estimates of reserves and future net
revenues, exploration and development activities in respect of the Umusadege
field, the Company's ability to finance its drilling and development plans with
cash flows from operations, the ability of the Company to successfully drill and
complete future wells, the ability of the Company to commercially produce,
transport and sell oil from the Umusadege field, future anticipated production
rates, export pipeline capacity available to the Company, the expectation of the
Company that production and export pipeline disruptions will not have a lasting
impact on the Company's future production, timing of completion of the Company's
upgrading of the central production facility, the construction and completion of
an alternative export pipeline, the acceptance of the Company's tax filings by
the Nigerian taxing authorities, treatment under government regulatory regimes
including royalty and tax laws, projections of market prices and costs, supply
and demand for oil, timing for receipt of government approvals, and the ability
of the Company to satisfy its current and future financial obligations to its
banks and other creditors.

There can be no assurance that such forward-looking statements will prove to be
accurate as actual results and future events could vary or differ materially
from those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements contained in this news release.
This cautionary statement expressly qualifies the forward-looking statements
contained herein.

Forward-looking statements are made based on management's beliefs, estimates and
opinions on the date the statements are made and the Company undertakes no
obligation to update forward-looking statements and if these beliefs, estimates
and opinions or other circumstances should change, except as required by
applicable law.

SOURCE: Mart Resources, Inc.



CONTACT: Mart Resources, Inc. - London, England office

Wade Cherwayko

+44 207 351 7937

Wade@martresources.com

www.martresources.com

Investor Inquiries:

FronTier Consulting Ltd.

Sam Grier or Caleb Gilani

Investor Relations Specialists

Toll Free: 1-888-875-7485

inquiries@martresources.com




Copyright (C) 2012 Marketwire. All rights reserved.

-0-




INDUSTRY KEYWORD: Energy and Utilities\Oil and Gas

SUBJECT CODE: EARNINGS

Mart Announces Record Financial and Operating Results for the Year Ended
December 31, 2011


CALGARY, ALBERTA, May 1, 2012 (Marketwire via COMTEX) -- Mart Resources, Inc.
(TSX VENTURE:MMT) ("Mart" or the "Company") is pleased to announce its financial
and operating results for the year ended December 31, 2011 (all amounts in
Canadian dollars unless noted):

YEAR ENDED DECEMBER 31, 2011







-- Net income for the year ended December 31, 2011 totaled $71.8 million

($0.214 per share), compared to net income of $8.7 million ($0.026 per

share) for the year ended December 31, 2010.



-- Funds flow from production operations were $144.1 million ($0.429 per

share) for the year ended December 31, 2011 compared to $48.2 million

($0.144 per share) for the year ended December 31, 2010 (see note (1)

regarding non-IFRS measures under the table below).



-- The average price received by Mart for oil in 2011 was USD $103.21 per

barrel of oil ("bbl") (approximately CDN $102.08 per bbl), compared to

USD $81.70 per bbl (approximately CDN $84.07 per bbl) in 2010.



-- Mart's share of Umusadege field oil produced and sold for the year ended

December 31, 2011 was 1,803,459 bbls compared to 732,101 bbls for the

year ended December 31, 2010. The main reason for the production

increase was the additions of UMU-8, UMU-7, and UMU-6 wells coupled with

an increase in cost oil recovery from 67% to an average rate of 71%

during the year.



-- Mart's share of proved Umusadege gross oil reserves after tax increased

by 15% to 10.5 million bbls compared to 9.1 million bbls in 2010.



-- Mart's share of proved plus probable Umusadege gross oil reserves after

tax increased by 16% to 13.9 million bbls compared to 12.0 million bbls

in 2010.



-- In 2011 the Umusadege field had a total of 50 shut-in days due mainly to

export pipeline disruptions, and to maintenance and modification of

production facilities, compared to a total of 92 shut-in days in 2010.



-- Mart's average daily oil production for 2011 was 4,941 barrels oil per

day ("bopd") compared to 2,005 bopd in 2010.





THREE MONTH PERIOD ENDED DECEMBER 31, 2011







-- Net income for Q411 was $21.1 million ($0.063 per share) compared to net

income of $2.1 million ($0.006 per share) for Q410.



-- Funds flow from production operations of $36.9 million ($0.110 per

share) for Q411 compared to $6.7 million ($0.020 per share) for Q410

(see note (1) regarding non-IFRS measures under the table below).



-- The average price received by Mart for oil in Q411 was USD $109.69 per

bbl (approximately CDN $108.49 per bbl) compared to USD $89.21 (CDN

$96.86 per bbl) for Q410.



-- Mart's share of Umusadege field oil produced and sold for the three

months ended December 31, 2011 ("Q411") was 432,166 bbls compared to

104,255 bbls for the three months ended December 31, 2010 ("Q410").



-- During Q411, the Umusadege field was shut-in for a total of 17 days

(Q410 65 days) due to various disruptions in the export pipeline and

maintenance and modification of production facilities.



-- UMU-8 well started producing in December 2011 and UMU-9 well was logged

showing 260 feet of pay.



-- Mart's average daily oil production for Q411 was 4,697 bopd compared to

1,158 bopd for Q410.





FINANCIAL AND OPERATING RESULTS

The following table provides a summary of Mart's selected financial and
operating results for the three month period ended and the years ended December
31, 2011 and 2010:







3 months 3 months 12 months 12 months

(CDN$) ended ended ended ended

Dec 31, Dec 31, Dec 31, Dec 31,

2011 2010 2011 2010

-----------------------------------------------------

Mart's share of the Umusadege

Field:

Barrels of oil produced

and sold 432,166 104,255 1,803,459 732,101

Average sales price per

barrel $ 108.485 $ 96.864 $ 102.081 $ 84.073

Mart's percentage share

of total Umusadege oil

produced and sold

during the period 77% 76% 71% 67%

Mart's share of

petroleum sales after

royalties 40,945,141 9,027,052 162,431,467 56,524,797

Funds flow from

production operations

(1) 36,927,682 6,677,197 144,129,393 48,235,615



Basic $ 0.110 $ 0.020 $ 0.429 $ 0.144



Net income 21,123,991 $ 2,127,266 71,801,346 8,698,547

Per share - basic $ 0.063 $ 0.006 $ 0.214 $ 0.026

Per share - diluted $ 0.061 $ 0.006 $ 0.209 $ 0.025



Total assets 198,021,112 118,766,739 198,021,112 118,766,739

Total bank debt Nil 5,627,778 Nil 5,627,778



Shares outstanding - end of period:



Basic 336,084,275 335,548,201 336,084,275 335,548,201

Diluted 344,318,066 342,184,661 344,318,066 342,184,661



Notes:



(1) Indicates non-IFRS measures. Non-IFRS measures are informative measures

commonly used in the oil and gas industry. Such measures do not conform to

IFRS and may not be comparable to those reported by other companies nor

should they be viewed as an alternative to other measures of financial

performance calculated in accordance with IFRS. For the purposes of this

table, the Company defines "Funds flow from production operations" as net

petroleum sales less royalties, community development costs and production

costs. Funds flow from production operations is intended to give a

comparative indication of the Company's net petroleum sales less production

costs as shown in the following table:



(CDN$) 3 months 3 months 12 months 12 months

ended ended ended ended

Dec 31, 2011 Dec 31, 2010 Dec 31, 2011 Dec 31, 2010

----------------------------------------------------------------------------

Petroleum sales 46,883,574 10,098,585 184,100,445 61,549,645

Less: Royalties and

community development

costs 5,938,433 1,071,533 21,668,978 5,024,848

----------------------------------------------------------------------------

Net petroleum sales 40,945,141 9,027,052 162,431,467 56,524,797

Less: Production costs 4,017,459 2,349,855 18,302,074 8,289,182

----------------------------------------------------------------------------

Funds flow from

production operations 36,927,682 6,677,197 144,129,393 48,235,615

----------------------------------------------------------------------------

----------------------------------------------------------------------------





RESERVES UPDATE:

Mart's total gross proved ("1P") oil reserves in the Umusadege field increased
16% to approximately 11.2 million bbls compared to 9.6 million bbls at December
31, 2010. Mart's total gross proved plus probable ("2P") oil reserves in the
Umusadege field increased 15% to approximately 14.9 million bbls compared to
12.9 million bbls at December 31, 2010. Mart's total gross proved plus probable
plus possible ("3P") oil reserves in the Umusadege field increased 9% to
approximately 22.0 million bbls compared to 20.1 million at December 31, 2010.

OUTLOOK AND OPERATIONS UPDATE:

The UMU-9 well was drilled to a depth of approximately 10,848 feet. The
intermediate section was drilled to 8,311 feet and indicated 260 feet of gross
oil pay from eleven sands based on open hole logs, and the lower deviated
section of the well was drilled from 8,311 feet to 10,848 feet and indicated an
additional 170 feet of gross oil pay in eight sands based on open hole logs.
This resulted in a total cumulative gross oil pay of approximately 430 feet of
19 sands encountered by the well. Nine sands were identified in the deviated
section of the UMU-9 well: three oil bearing sands (XVIa, XV1b, XVIIa) that had
been encountered in previous Umusadege wells and six new sands that were
discovered by the UMU-9 well. Detailed fluid analysis was conducted on five out
of the six new sands, and lab analysis has confirmed that four sands (XVIIb,
XVIIIa, XIX, XXb) contain light oil and condensate and one sand (XVIIIB)
contains gas condensate. The remaining four sands did not have fluid analysis
conducted, however open hole logs indicated the presence of hydrocarbons.

Completion and testing operations were conducted on the UMU-9 well in Q112. The
test of the XIV sand was conducted through a 3 1/2 inch tubing on a 32/64 inch
choke at a flowing tubing pressure of 480 psi. The well flowed 43 API gravity
oil with BS&W of 0.2% and an oil/gas ratio of approximately 90 standard cubic
feet per barrel. The 46 foot XIV sand flowed at a stabilized test rate of 4,240
bopd.

During the commingled test of the XIIIa and XIIIb sands, the well flowed 42 API
gravity oil through 3 1/2 inch tubing on a 28/64 inch choke at a flowing tubing
pressure of 350 psi. Basic sediment and water (BS&W) was 1.0% with no associated
gas. A stabilized flow rate of 2,576 bopd was recorded from the commingled 16
foot XIIIa and 15 foot XIIIb sands.

The test of the XIIa sand was conducted through the 2 7/8 inch tubing on a 30/64
inch choke at a flowing tubing pressure of 290 psi. The well flowed 35 API
gravity oil with BS&W of 0.8% with no associated gas. The 30 foot XIIa sand
flowed at a stabilized test rate of 3,600 bopd.

The test of the X sand was conducted through the 2 7/8 inch tubing on a 28/64
inch choke at a flowing tubing pressure of 160 psi. The well flowed 40 API
gravity oil with BS&W of 0.6% and an oil/gas ratio of 43 standard cubic feet per
barrel. The 10 foot X sand flowed at a stabilized test rate of 1,300 bopd.

The combined flow rate of the five sands tested in the UMU-9 well is 11,718
bopd. Reserve reports will be updated at a future date to incorporate the
results from the UMU-9 well.

To mitigate risks relating to export pipeline capacity, Mart and its
co-venturers continue to evaluate new export pipeline options to provide an
alternative for future production capacity. Mart and its co-venturers are
currently in discussion with an affiliate of Royal Dutch Shell plc, to provide
another independent export pipeline for Umusadege field production. If these
discussions result in Mart and its co-venturers gaining access to Shell's export
facilities, a new 50 kilometer pipeline will be constructed. The upgrade of the
central production facility at the Umusadege field to a design capacity of
approximately 30,000 bopd is approximately 75% completed.

Subsequent to December 31, 2011, the Company entered into an agreement pursuant
to which Mart and Network Exploration & Production Nigeria Limited have amicably
terminated Mart's participating interest in the Qua Ibo field. Under the terms
of the agreement, Network has assumed responsibility for outstanding liabilities
of approximately USD $3.2 million for the Qua Ibo field and has paid Mart a USD
$1.0 million termination fee.

CHAIRMAN'S COMMENT:

Wade Cherwayko, Chairman & CEO of Mart said, "We are very pleased to report
record financial and operating results for 2011 with $71.8 million of net
income, which amounts to $0.214 per share. This continues to demonstrate the
significance of the Umusadege field's production capacity. The Company continues
to work towards maximizing production and efficiency, and significant steps have
been taken towards building an additional export pipeline to enable us to fully
exploit the potential of the Umusadege field. Increasing total pipeline capacity
will provide the ability to substantially increase production and cash flow.
Mart has also had a substantial increase in its share of reserves at the
Umusadege field in 2011 as the direct result of continued successful drilling."

ABOUT MART RESOURCES:

Mart Resources, Inc. is an independent, international petroleum company focused
on drilling, developing and producing oil and gas from proven petroleum
properties in Nigeria, West Africa. The Company is currently producing and
developing the Umusadege field along with Midwestern Oil and Gas Co. Plc (the
Operator of the field) and SunTrust Oil Ltd. Mart also owns a land drilling rig,
has strong local relationships and experience and is evaluating additional
proven undeveloped opportunities in Nigeria.

For more information, please contact Wade Cherwayko at Mart's London, England
office # +44 207 351 7937 or e-mail: Wade@martresources.com. Additional
information regarding Mart Resources, Inc. is available on the company's website
at www.martresources.com and under the Company's profile on SEDAR at
www.sedar.com.

INVESTOR RELATIONS:

Investors are also welcome to contact one of the following investor relations
specialists for all corporate updates and investor inquiries:

FronTier Consulting Ltd.

Mart toll free # 1-888-875-7485

Attn: Sam Grier or Caleb Gilani

Email: inquiries@martresources.com

Note: Except where expressly stated otherwise, all production figures set out in
this press release, including bopd, reflect gross Umusadege field production
rather than production attributable to Mart. Mart's share of total gross
production before taxes and royalties from the Umusadege field fluctuates
between 82.5% (before capital cost recovery) and 50% (after capital cost
recovery).

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking
statements" as such term is used in applicable Canadian and US securities laws.
Any statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, assumptions or future
events or are not statements of historical fact and should be viewed as
"forward-looking statements". These statements relate to analyses and other
information that are based upon forecasts of future results, estimates of
amounts not yet determinable and assumptions of management. Such forward looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements.

In particular, statements (express or implied) contained herein or in Mart's
MD&A regarding the following should be considered forward-looking statements:
the Company's goals and growth strategy, estimates of reserves and future net
revenues, exploration and development activities in respect of the Umusadege
field, the Company's ability to finance its drilling and development plans with
cash flows from operations, the ability of the Company to successfully drill and
complete future wells, the ability of the Company to commercially produce,
transport and sell oil from the Umusadege field, future anticipated production
rates, export pipeline capacity available to the Company, the expectation of the
Company that production and export pipeline disruptions will not have a lasting
impact on the Company's future production, timing of completion of the Company's
upgrading of the central production facility, the construction and completion of
an alternative export pipeline, the acceptance of the Company's tax filings by
the Nigerian taxing authorities, treatment under government regulatory regimes
including royalty and tax laws, projections of market prices and costs, supply
and demand for oil, timing for receipt of government approvals, and the ability
of the Company to satisfy its current and future financial obligations to its
banks and other creditors.

There can be no assurance that such forward-looking statements will prove to be
accurate as actual results and future events could vary or differ materially
from those anticipated in such statements. Accordingly, readers should not place
undue reliance on forward-looking statements contained in this news release.
This cautionary statement expressly qualifies the forward-looking statements
contained herein.

Forward-looking statements are made based on management's beliefs, estimates and
opinions on the date the statements are made and the Company undertakes no
obligation to update forward-looking statements and if these beliefs, estimates
and opinions or other circumstances should change, except as required by
applicable law.

SOURCE: Mart Resources, Inc.



CONTACT: Mart Resources, Inc. - London, England office

Wade Cherwayko

+44 207 351 7937

Wade@martresources.com

www.martresources.com

Investor Inquiries:

FronTier Consulting Ltd.

Sam Grier or Caleb Gilani

Investor Relations Specialists

Toll Free: 1-888-875-7485

inquiries@martresources.com




Copyright (C) 2012 Marketwire. All rights reserved.

-0-




INDUSTRY KEYWORD: Energy and Utilities\Oil and Gas

SUBJECT CODE: EARNINGS

ATPG


GE Receives $80 Million Contract from ATP Oil & Gas for Cheviot Oilfield
Project in the North Sea
GE Technology Will Enable ATP to Revamp Existing
Oilfield


HOUSTON, Apr 30, 2012 (BUSINESS WIRE) --
--GE Equipment Chosen for Highest Levels of Reliability and Safety

GE Oil & Gas (NYSE: GE) will supply ATP Oil & Gas (UK) Limited with subsea
production equipment, ancillary systems and related services for
ATP's signature Cheviot oilfield project in the North
Sea, under the terms of an $80 million contract. ATP is a unit of Houston,
Texas-based ATP Oil & Gas Corporation (NASDAQ: ATPG).

The Cheviot Field lies approximately 100 kilometers (km) east of the Shetland
Isles in the northern part of the North Sea and is a redevelopment of a previous
field with still significant reserves that ATP can recover economically and with
modern technology.

The GE equipment, including wellheads, subsea Xmas trees and a subsea control
system, will be used in conjunction with ATP's
"Octabuoy" Floating
Production and Storage Facility (FPS), a state-of-the-art vessel currently under
construction. As part of the contract, GE also will provide system engineering
and design, procurement and on-site testing services. Product shipments will
begin in February 2013 with installation later in the year. Commercial
operations are expected to begin in 2014.

GE's Wellstream unit was previously awarded a
contract to supply ATP's project management
contractor with 45 km of flexible risers and flowline products for the Cheviot
FPS facility. This reusable floating production and storage facility is expected
to be relocated to other fields around the world after it has fully produced the
Cheviot reserves.

This award confirms GE's capability to efficiently
manage different activities across several business sectors and customer offices
in the U.K. and Houston in order to offer tailored solutions to specific
customer requirements.

"This project is a good example of how GE can marshal
extensive resources in order to help customers meet business challenges as well
as technical problems," said Rod Christie, vice
president, subsea systems of GE Oil & Gas. "ATP was
looking for high reliability, the lowest lifecycle cost and the ability to meet
a very tight schedule. To meet these requirements, GE offered proven
fit-for-purpose equipment based on our experience with comparable projects,
along with world-class engineering and other services to speed installation and
testing."

About GE

GE (NYSE: GE) works on things that matter. The best people and the best
technologies taking on the toughest challenges. Finding solutions in energy,
health and home, transportation and finance. Building, powering, moving and
curing the world. Not just imagining. Doing. GE works. For more information,
visit the company's website at www.ge.com.

GE Energy works connecting people and ideas everywhere to create advanced
technologies for powering a cleaner, more productive world. With more than
100,000 employees in over 100 countries, our diverse portfolio of product and
service solutions and deep industry expertise help our customers solve their
challenges locally. We serve the energy sector with technologies in such areas
as natural gas, oil, coal and nuclear energy; wind, solar, biogas and water
processing; energy management; and grid modernization. We also offer integrated
solutions to serve energy- and water-intensive industries such as mining,
metals, marine, petrochemical, food & beverage and unconventional fuels.

Follow GE Energy on Twitter @GE_Energy.

SOURCE: GE



CONTACT:
GE Oil & Gas
Fabio Pianini
+39 055 423 8872
fabio.pianini@ge.com
or
Masto Public Relations
Ken Darling
+1 518 786 6488
kenneth.darling@ge.com




Copyright Business Wire 2012

-0-




KEYWORD: United Kingdom

United States

Europe

North America

Texas

INDUSTRY KEYWORD: Energy

Alternative Energy

Oil/Gas

Utilities

Other Energy

Manufacturing

Engineering

Other Manufacturing

SUBJECT CODE: Contract/Agreement

BOSTON, April 30, 2012 /PRNewswire via COMTEX/ -- Solos Endoscopy, Inc. (OTCPK:
SNDY) is pleased to announce that the Company expects to show a sales increase
of more than 16% as compared to the same period last year when it posts its
first quarter financials for period ended March 31, 2012.

Solos Endoscopy's sales increased from $84,185 for the period ended March 31,
2011 to $97,760 for the same period this year. Solos management expects the
positive trend to continue as the demand for endoscopic instruments has been
increasing Worldwide.

Solos Endoscopy has developed several new modifications to its endoscopic
instrument lines to accommodate the continual advances in Laparoscopic surgical
procedures. The significant advances over the past several years have led to a
number of advantages to the patient with laparoscopic surgery versus an open
procedure (laparotomy). The demand for endoscope services is increasing due to
an increase in the aging and chronically ill population worldwide. Advancements
in endoscopic technologies and inclusion of various types of lighting sources,
video cameras, real-time conversion of data into three-dimensional images are
also driving this market.

Solos Endoscopy expects to post its first quarter financials on the OTC Markets
website within the next two weeks. The Company will also be releasing it's
"President's Report" for distribution to its shareholders in the next thirty
days.

"I am very pleased with the positive turnaround. Solos has been able to reduce
its debts and increase its sales in a very short period of time. We believe the
Company is well positioned for profitability," stated Bob Segersten, President
of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to
develop and market high quality and innovative instruments for the screening,
diagnosis, treatment and management of medical conditions. Additional
information on its FDA approved products is available on the Company's website
at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information
within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6
under the Securities Exchange Act of 1934, and are subject to the safe harbor
created by those rules. All statements, other than statements of fact, included
in this release, including, without limitation, statements regarding potential
future plans and objectives of the company, are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such statements
will prove to be accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical complications
that may arise could prevent the prompt implementation of any strategically
significant plan(s) outlined above. The company cautions that these
forward-looking statements are further qualified by other factors including, but
not limited to, those set forth in the company's Annual Report filing and other
filings with the Pink OTC Markets (available at www.otcmarkets.com). The company
undertakes no obligation to publicly update or revise any statements in this
release, whether as a result of new information, future events, or
otherwise.CONTACT: AMANDA SEGERSTEN

LAKELAND, FL, Apr 30, 2012 (MARKETWIRE via COMTEX) -- Coda Octopus Group, Inc.
(PINKSHEETS: CDOC) was recently awarded and completed a contract for circa $3m
for the supply of six (6) of its Underwater Inspection Systems (UIS(TM)) to the
Lower Mississippi River Port-Wide Strategic Security Council. These systems will
be used by a number of ports in that region.

The Lower Mississippi River is reported to be the largest and one of the busiest
port systems in the world. It is also fast moving and has almost zero visibility
water, making it amongst the most difficult port environments to maintain. Each
of these UIS(TM) systems which include Echoscope(R) real-time 3D sonar
technology will be used, amongst other things, for essential safety duties, such
as ensuring that the shipping channels are kept clear of dangerous debris.

Blair Cunningham, our Chief Technology Officer, said, "We are very pleased to
welcome this very influential group of Louisiana ports to the fast growing
community of UIS(TM) users. The Coda Octopus UIS(TM) is proving itself
invaluable to operators. By using its real-time 3D capabilities it is providing
cost and time savings by enabling operators to see in real time underwater
objects in zero visibility conditions and thereby reducing significantly the
complexity of tasks and operations. We now have over 25 UIS(TM) in operation in
the US ports community, doing essential port and harbor security work every day
of the year. This is a testament to the incontrovertible benefits of deploying
this real time tool."

About Coda Octopus Group, Inc. Originally founded in 1994 as Coda Technologies,
the Coda Octopus Group is now headquartered in Lakeland, Florida. The Group
consists of a Marine Products business in Florida and Edinburgh, Scotland, and
engineering businesses in Utah and Weymouth, England. Each of the Group
companies are technology innovators with a particularly high level of sonar
expertise. The Group has facilities in Florida, Utah, the UK and Norway.

Alongside providing custom engineering and development for defense applications,
and oil and gas, companies, one of the Group's key products is the Coda
Echoscope(R) -- the first real time 3D sub-sea sonar. The Echoscope(R) is also
at the heart of the Underwater Inspection System(TM) which is being adopted for
homeland security, and other applications in ports around the world.

With this patented revolutionizing sub-sea visualization capability, and the
existing systems integration skills within Colmek Systems Engineering, Inc. and
Martech Systems Engineering Ltd., the Coda Octopus Group believes they can
become a world leading integrated sonar technology supplier.

For further information, please visit http://www.codaoctopusgroup.com or contact
Coda Octopus at info@codaoctopusgroup.com.

Safe Harbor Statement: This press release contains certain forward-looking
statements. These forward-looking statements can generally be identified as such
because the context of the statement will include words such as Coda Octopus
Group plans, expects, should, believes, anticipates or words of similar import.
Stockholders, potential investors and other readers are cautioned that these
forward-looking statements are predictions based only on current information and
expectations that are inherently subject to risks and uncertainties that could
cause future events or results to differ materially from those set forth or
implied by the forward-looking statements. Certain of those risks and
uncertainties are discussed in registration statement on Form SB-2 and include,
but are not limited to, market acceptance of Coda Octopus' planned products and
their level of sales, access to the capital necessary to finance and grow the
business, a highly competitive environment in the security field that includes
numerous large and well established companies much larger than ours, and our
ability successfully to deploy our technologies and products to meet the
technical demands and market requirements of our customers. These
forward-looking statements are only made as of the date of this press release
and Coda Octopus Group does not undertake any obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.





Company Contact:

Geoff Turner

Director and Group Officer

info@codaoctopusgroup.com





SOURCE: Coda Octopus Group, Inc.




CONTACT: mailto:info@codaoctopusgroup.com




Copyright 2012 Marketwire, Inc., All rights reserved.

-0-




SUBJECT CODE: Aerospace and Defense:Electronics and Communications

Aerospace and Defense:Marinecraft

Electronics and Semiconductors:Electronic Components

Yangarra Provides a Working Capital Update, Files its Annual Information
Form and Updates its Corporate Presentation


CALGARY, Apr 27, 2012, 2012 (Canada NewsWire via COMTEX) -- Yangarra Resources
Ltd. ("Yangarra" or the "Company") (TSX-V:YGR) is pleased to provide a working
capital update, announce the filing of its Annual Information Form and provide
an updated corporate presentation.

Working Capital Update

The Company's working capital deficiency, including bank debt and excluding the
mark to market on commodity contracts, was approximately $34 million at the end
of the first quarter 2012 and is currently approximately $32 million. The
Company's credit facility with Alberta Treasury Branches ("ATB") has a limit of
$42 million.

Annual Information Form

The Company's Annual Information Form will be filed on SEDAR (www.sedar.com) and
is currently available on the Company's website:


http://www.yangarra.ca/Financial-Reports/Financial-Reports/Annual-Information-Forms/

The Annual Information Form includes the Company's reserves and resource data
for the period ended December 31, 2011 as evaluated by AJM Deloitte and other
oil and natural gas information prepared in accordance with National Instrument
51-101 Standards of Disclosure for Oil and Gas Activities.

Yangarra has also previously filed its audited financial statements and
accompanying notes for the year ended December 31, 2011 and related Management
Discussion and Analysis with Canadian Securities Regulatory Authorities. Copies
of Yangarra disclosure documents may be obtained at www.sedar.com or on the
Company's website:

http://www.yangarra.ca/Financial-Reports/Financial-Reports/Annual-Reports/

Corporate Presentation

Bravo International Services to Provide Investor Relations Services to
LIG Assets, Inc.


DALLAS, April 26, 2012 /PRNewswire via COMTEX/ -- LIG Assets, Inc. (OTCPK:
LIGA) has retained Bravo International Services, a full-service Investor
Relations Company since 1989, to provide Investor Relations Services. Bravo
plans to help build the Company's shareholder base, disseminate news and
profiles about the Company to prospective investors, answer shareholder
inquiries via email, and help handle investor relations phone calls.

President Larry K. Davis stated, "Bravo International aims to deliver long-term
investor relations strategies that will reach different classes of investors as
its customers' businesses grow. We researched LIG Assets, Inc. from top to
bottom and believe the stock to be significantly undervalued and underfollowed
by the investment community."

Under the terms of the Agreement, Bravo International, Inc. received a retainer
of $15,000 in cash and expects to receive $5,000 per month on a month to month
basis.

About Bravo International Services:

http://ih.advfn.com/p.php?pid=nmona&article=52130692

Riverdale Oil and Gas Corporation (RVDO.PK) Announces New Oil and Gas Interests
Print
Alert
Riverdale Oil & Gas Corp (PC) (USOTC:RVDO)
Intraday Stock Chart
Today : Friday 20 April 2012


Riverdale Oil and Gas Corporation (PINKSHEETS: RVDO) announced five (5) additional oil and gas interest acquisitions at its Annual Meeting of Stockholders in Austin, Texas, on Monday the 16th of April, 2012. The acquisitions would add a significant increase to the potential reserves that Riverdale could own, once those interests are drilled.
A three (3) well program, of which Riverdale owns a 0.9375% Carried Working Interest (CWI), is scheduled for drilling early in the Second Quarter, 2012. It also owns a 1% CWI in a well that is scheduled to be drilled before the end of the Second Quarter, 2012. Additionally, Riverdale has recently acquired a 1% CWI in an abandoned gas well, scheduled for completion this following week, in the first of two well defined, untapped gas sands behind the casing.

The majority of Riverdale's oil and gas acquisitions are currently directed towards oil production, with gas prospects being defined by low development costs versus high potential rates of production.

All of the oil and gas projects that these acquired interests were selected from, are based upon state-of-the-art 3D Seismic with a proprietary Neural Network software evaluation procedure.

The objective of Riverdale will continue to be acquiring affordable, high quality interests in multiple oil and gas projects, which should maintain stability for Riverdale Oil and Gas Corporation stock, while fostering diversity and a controlled growth in its asset base.

Media Contact:

Linda Ellis

VP Investor Relations

Direct # 512-687-1114

Email: Email Contact

i got 4 news alerts

Of course he is..he is a man of his word.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74265129

PLOP

NEW YORK, NY, Apr 12, 2012 (MARKETWIRE via COMTEX) -- Chinese small cap stocks
have been red hot recently. Chinese based companies have been some of the
biggest movers in the market recently, with gains for these companies ranging
from 20 percent to as high as 180 percent over the past week. The Paragon Report
examines the outlook for China's small cap stocks and provides investment
research on SmartHeat Inc. (NASDAQ: HEAT) and Guanwei Recycling Corp. (NASDAQ:
GPRC).

Access to the full company reports can be found at:

www.ParagonReport.com/HEAT www.ParagonReport.com/GPRC

While a few of these companies had their own reasons for the sudden spikes,
there has been one common factor. The China Securities Regulatory Commission
(CSRC) nearly tripled the quotas for qualified foreign institutional investors
to 80 billion Yuan from the previous limit of 30 billion Yuan. This will allow
offshore investors to inject an extra $50 billion Yuan ($7.95 billion) into the
country.

Although the dollar amount was not a significant sum it was still symbolically
important as it appears that China is loosening its grip on their tightly
controlled capital markets. The "move is a sign of a push for greater capital
account opening," said Dariusz Kowalczyk, a senior economist at Credit Agricole
in Hong Kong. "It is also a step toward attracting more foreign investment."

The Paragon Report provides investors with an excellent first step in their due
diligence by providing daily trading ideas, and consolidating the public
information available on them. For more investment research on China's small cap
stocks register with us free at www.ParagonReport.com and get exclusive access
to our numerous stock reports and industry newsletters.

SmartHeat Inc., a market leader in China's clean technology, energy savings
industry, announced financial results for the fiscal year ended December 31,
2011. Mainly due to goodwill impairment of $8.96 million taken in Q4 2011, the
company experienced an operating loss of $8.82 million in Q42011 compared to an
operating loss of $2.54 million in Q3 2011 and a net loss for Q42011 of $9.59
million compared to net loss of $4.0 million for Q3 2011. If not for one-time
impairments to goodwill and inventory taken in Q4 2011, their operating loss
would have resulted in operating income of approximately $3.77 million in Q4
2011 compared to operating loss of $2.54 million in Q3 2011.

Guanwei Recycling Corp., China's leading clean tech manufacturer of recycled low
density polyethylene (LDPE), reported record sales and profits in 2011.
Continuing strong domestic demand for the high quality, competitively priced
recycled plastic manufactured at its zero discharge facility, also is expected
to produce another year of record growth in 2012.

The Paragon Report has not been compensated by any of the above-mentioned
publicly traded companies. Paragon Report is compensated by other third party
organizations for advertising services. We act as an independent research portal
and are aware that all investment entails inherent risks. Please view the full
disclaimer at: http://www.ParagonReport.com/disclaimer

SOURCE: Paragon Financial Limited





Copyright 2012 Marketwire, Inc., All rights reserved.

-0-

NEW YORK, NY, Apr 12, 2012 (MARKETWIRE via COMTEX) -- Chinese small cap stocks
have been red hot recently. Chinese based companies have been some of the
biggest movers in the market recently, with gains for these companies ranging
from 20 percent to as high as 180 percent over the past week. The Paragon Report
examines the outlook for China's small cap stocks and provides investment
research on SmartHeat Inc. (NASDAQ: HEAT) and Guanwei Recycling Corp. (NASDAQ:
GPRC).

Access to the full company reports can be found at:

www.ParagonReport.com/HEAT www.ParagonReport.com/GPRC

While a few of these companies had their own reasons for the sudden spikes,
there has been one common factor. The China Securities Regulatory Commission
(CSRC) nearly tripled the quotas for qualified foreign institutional investors
to 80 billion Yuan from the previous limit of 30 billion Yuan. This will allow
offshore investors to inject an extra $50 billion Yuan ($7.95 billion) into the
country.

Although the dollar amount was not a significant sum it was still symbolically
important as it appears that China is loosening its grip on their tightly
controlled capital markets. The "move is a sign of a push for greater capital
account opening," said Dariusz Kowalczyk, a senior economist at Credit Agricole
in Hong Kong. "It is also a step toward attracting more foreign investment."

The Paragon Report provides investors with an excellent first step in their due
diligence by providing daily trading ideas, and consolidating the public
information available on them. For more investment research on China's small cap
stocks register with us free at www.ParagonReport.com and get exclusive access
to our numerous stock reports and industry newsletters.

SmartHeat Inc., a market leader in China's clean technology, energy savings
industry, announced financial results for the fiscal year ended December 31,
2011. Mainly due to goodwill impairment of $8.96 million taken in Q4 2011, the
company experienced an operating loss of $8.82 million in Q42011 compared to an
operating loss of $2.54 million in Q3 2011 and a net loss for Q42011 of $9.59
million compared to net loss of $4.0 million for Q3 2011. If not for one-time
impairments to goodwill and inventory taken in Q4 2011, their operating loss
would have resulted in operating income of approximately $3.77 million in Q4
2011 compared to operating loss of $2.54 million in Q3 2011.

Guanwei Recycling Corp., China's leading clean tech manufacturer of recycled low
density polyethylene (LDPE), reported record sales and profits in 2011.
Continuing strong domestic demand for the high quality, competitively priced
recycled plastic manufactured at its zero discharge facility, also is expected
to produce another year of record growth in 2012.

The Paragon Report has not been compensated by any of the above-mentioned
publicly traded companies. Paragon Report is compensated by other third party
organizations for advertising services. We act as an independent research portal
and are aware that all investment entails inherent risks. Please view the full
disclaimer at: http://www.ParagonReport.com/disclaimer

SOURCE: Paragon Financial Limited





Copyright 2012 Marketwire, Inc., All rights reserved.

-0-

LDRXF..Leader Energy Services Q4 net income increases


Apr 11, 2012 (Datamonitor via COMTEX) -- Leader Energy Services Ltd, a provider
of coiled tubing and nitrogen pumping services to the oil and gas industry, has
reported that net income for the fourth quarter ended December 31, 2011 was
C$1.96 million, or C$0.09 per diluted share, compared to C$1.1 million, or
C$0.03 per diluted share, for the same quarter ended December 31, 2010.

Revenue for the fourth quarter ended December 31, 2011 was C$11.14 million,
compared to C$8.77 million for the same quarter ended December 31, 2010.

Net income for the year ended December 31, 2011 was C$1.84 million, or C$0.08
per diluted share, compared to C$2.18 million, or C$0.08 per diluted share, for
the year ended December 31, 2010.

MAUXF...Mart Resources, Inc.: March 2012 Operational Update
- Umusadege field
production averaged 12,176 barrels of oil per day ("bopd") during March based on
production days - Umusadege field net deliveries into export storage tanks were
approximately 351,400 barrels of oil during March - Development drilling program
continues with rig move to UMU-10

Copycat

HLXH - 11:40:49
Bought 5000s @ $0.0444 - Total: $230.11

My WAG...about 2.50, or more if Chinese stocks stay hot as they are now.

392 million for 40k shares. LOL

I didn't even pay 1 million for all my shares.

http://www.mmdnewswire.com/12-98582.html

Insider at Repro Med Systems Inc (REPR), Mark Pastreich, buys USD 392M of stock


CHESTER, NY (MMD Newswire) March 23, 2012 -- Mark Pastreich purchased 40,000 shares of Repro Med Systems Inc stock, or $392,000,000 worth, as noted in an SEC Filing today. As reported in the filing, the transactions occurred on March 20, 2012.

After the transaction, Mark Pastreich's stake was reported as 111,500 shares of Repro Med Systems Inc stock. Mark Pastreich's title was listed as "Director" at Repro Med Systems Inc within the filing.

As noted on March 21, 2012, Mark Pastreich's purchase was done directly over 1 transaction on March 20, 2012. The share price for the transaction was $9,800 according to the regulatory filing detailing the trade.

If we look over the past 12 months, Mark Pastreich has sold no shares of Repro Med Systems Inc stock. Over the same time period, Mark Pastreich has purchased 40,000 shares of Repro Med Systems Inc, with a total cost of $392,000,000.

Let's take a quick, high-level look at insider trading at Repro Med Systems Inc over the past 12 months. No shares of Repro Med Systems Inc stock were sold by company insiders. Over the same time 12 month time period, 40,000 shares of Repro Med Systems Inc, for a total value of $392,000,000 were purchased by company insiders.

Source: SEC Filings

My picks

Winner of AL East Yankees
2nd In AL East Rays
Winner of AL Central Tigers
2nd In AL Central KC Royals
Winner of AL West Rangers
2nd In AL West Angels
AL Wildcard #1 Angels
AL Wildcard #2 Rays
Winner of NL East Phillies
2nd In NL East Braves
Winner of NL Central Cards
2nd In NL Central Reds
Winner of NL West D-backs
2nd In NL West Dodgers
NL Wildcard #1 Braves
NL Wildcard #2 Dodgers

Team With Best Record In Baseball Tigers
Team With Worst Record In Baseball Astros

TB # 1: Who hits the most HR in Baseball Bautista
TB # 2: Who has the Most RBIS in Baseball M Cabrara(Detroit)

Thanks